[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 956
1. Rui D, Yongjian Y: Aluminum chloride induced oxidative damage on cells derived from hippocampus and cortex of ICR mice. Brain Res; 2010 Apr 9;1324:96-102
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Aluminum (Al) is among the most abundant elements on earth, it has been associated with the etiology of Alzheimer's disease.
  • In the present study, AlCl(3) was administered with the dose of 10, 50 or 300 mg/kg b.wt/day through diet for 100 days.
  • AlCl(3) exposure resulted in increased MDA levels accompanied by decreased activities of SOD in the cells.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20156420.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Chlorides; 0 / DNA, Mitochondrial; 0 / Oxidants; 3CYT62D3GA / aluminum chloride; EC 1.15.1.1 / Superoxide Dismutase
  •  go-up   go-down


2. Arroyo-Serralta GA, Kú-González A, Hernández-Sotomayor SM, Zúñiga Aguilar JJ: Exposure to toxic concentrations of aluminum activates a MAPK-like protein in cell suspension cultures of Coffea arabica. Plant Physiol Biochem; 2005 Jan;43(1):27-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Exposure to toxic concentrations of aluminum activates a MAPK-like protein in cell suspension cultures of Coffea arabica.
  • Addition of a toxic concentration of aluminum (Al) to cell suspension cultures of Coffea arabica L. induced the rapid and transient activation of a protein kinase that phosphorylates myelin basic protein (MBP), as revealed by in-gel kinase assays.
  • This enzyme with an apparent molecular mass of 58 kDa was activated shortly after cells were exposed to 50 microM AlCl(3), a concentration previously shown to produce toxicity in plant cells in vitro.
  • Analysis of the same cell extracts with antibodies that specifically recognize bis-phosphorylated (active) mitogen-activated protein kinases (MAP kinases), revealed the presence of a phosphoprotein with an apparent molecular mass of 58 kDa, which showed the same response to Al as the protein kinase revealed by the in-gel kinase assays.
  • Furthermore, immunoprecipitation with an antibody directed against mammalian MAP kinases depleted both the enzymatic activity and the phosphoprotein from the cell extracts, suggesting that the 58 kDa kinase and the 58 kDa phosphoprotein from C. arabica cells are the same protein, and that it can be actually a member of the MAP kinase family of protein kinases.
  • Since its activity is enhanced dramatically after addition of AlCl(3) to the medium, we can speculate that Al toxicity in plants could be perceived through the MAP kinase signal transduction pathway.

  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15763663.001).
  • [ISSN] 0981-9428
  • [Journal-full-title] Plant physiology and biochemistry : PPB
  • [ISO-abbreviation] Plant Physiol. Biochem.
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Caseins; 0 / Histones; 0 / Myelin Basic Protein; 0 / Plant Proteins; CPD4NFA903 / Aluminum
  •  go-up   go-down


3. Naeem S, Bukhari MH, Khurshid I, Hameed A: Bone marrow involvement in systemic ALK+ anaplastic large cell lymphoma: morphological resemblance with Hodgkin's lymphoma. J Coll Physicians Surg Pak; 2006 Feb;16(2):148-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bone marrow involvement in systemic ALK+ anaplastic large cell lymphoma: morphological resemblance with Hodgkin's lymphoma.
  • Diagnosis of anaplastic large cell lymphoma was made on lymph node biopsy and confirmed by immunohistochemistry using a panel of monoclonal antibodies including ALK-1.
  • Bone marrow aspiration revealed the presence of large lymphoma cells and trephine biopsy showed interstitial involvement.
  • All these features resulted in a strong resemblance of the morphology with Hodgkin's lymphoma.
  • [MeSH-major] Activin Receptors, Type II / metabolism. Bone Marrow / pathology. Hodgkin Disease / diagnosis. Lymphoma, Large B-Cell, Diffuse / pathology
  • [MeSH-minor] Adult. Anaplasia. Biopsy, Needle. Diagnosis, Differential. Humans. Immunohistochemistry. Male

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16499814.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Pakistan
  • [Chemical-registry-number] EC 2.7.11.30 / ACVRL1 protein, human; EC 2.7.11.30 / Activin Receptors, Type II
  •  go-up   go-down


Advertisement
4. Weinberg OK, Seo K, Arber DA: Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary? Hum Pathol; 2008 Sep;39(9):1331-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevalence of bone marrow involvement in systemic anaplastic large cell lymphoma: are immunohistochemical studies necessary?
  • The frequency of bone marrow involvement in anaplastic large cell lymphoma has been reported with great variation.
  • A prior study found that anaplastic large cell lymphoma involvement of bone marrow was often not evident on routine stains and advocated using immunohistochemical studies.
  • We evaluated 70 bone marrow biopsies from 41 patients with anaplastic large cell lymphoma and found 10 morphologically involved cases (14% of all biopsies, 22% of all patients).
  • In most cases (9/10 biopsies), the involvement of the bone marrow by anaplastic large cell lymphoma was massive and, thus, was evident on the hematoxylin and eosin section.
  • To determine if the hematoxylin and eosin evaluation missed bone marrow involvement, we used a panel of antibodies including CD30, ALK-1, epithelial membrane antigen, and granzyme.
  • Only the 10 morphologically involved cases showed anaplastic large cell lymphoma cells with distinct CD30 expression.
  • Other stains highlighted only a subset of the CD30-positive cases.
  • Overall, marrow involvement in anaplastic large cell lymphoma was relatively uncommon, and when present, it was identified on hematoxylin and eosin sections.
  • [MeSH-major] Bone Marrow / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adult. Aged, 80 and over. Antigens, CD30 / immunology. Child. Child, Preschool. Clone Cells / pathology. Eosine Yellowish-(YS). Female. Hematoxylin. Humans. Immunohistochemistry. Male. Middle Aged. Protein-Tyrosine Kinases / analysis. Receptor Protein-Tyrosine Kinases. Survival Analysis

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. HEMATOXYLIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18602674.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; TDQ283MPCW / Eosine Yellowish-(YS); YKM8PY2Z55 / Hematoxylin
  •  go-up   go-down


5. Pham AL, Lee C, Doyle FM, Sedlak DL: A silica-supported iron oxide catalyst capable of activating hydrogen peroxide at neutral pH values. Environ Sci Technol; 2009 Dec 1;43(23):8930-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Silica- and alumina-containing iron oxides prepared by sol-gel processing of aqueous solutions containing Fe(ClO(4))(3), AlCl(3), and tetraethyl orthosilicate efficiently catalyzed the decomposition of H(2)O(2) into oxidants capable of transforming phenol at circumneutral pH values.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FERRIC OXIDE .
  • Hazardous Substances Data Bank. HEMATITE .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Environ Sci Technol. 2007 Sep 1;41(17):6117-23 [17937290.001]
  • [Cites] Environ Sci Technol. 2008 Feb 15;42(4):1262-7 [18351103.001]
  • [Cites] Water Res. 2001 Jun;35(9):2291-9 [11358310.001]
  • [Cites] Water Res. 2005 May;39(9):1741-50 [15899272.001]
  • [Cites] Environ Sci Technol. 2002 Apr 1;36(7):1467-76 [11999052.001]
  • [Cites] Environ Sci Technol. 2003 Mar 1;37(5):972-8 [12666928.001]
  • [Cites] Environ Sci Technol. 2003 Mar 15;37(6):1150-8 [12680668.001]
  • [Cites] Environ Sci Technol. 2002 Feb 15;36(4):639-45 [11878378.001]
  • (PMID = 19943668.001).
  • [ISSN] 0013-936X
  • [Journal-full-title] Environmental science & technology
  • [ISO-abbreviation] Environ. Sci. Technol.
  • [Language] ENG
  • [Grant] United States / NIEHS NIH HHS / ES / ES004705-220031; United States / NIEHS NIH HHS / ES / P42 ES004705; United States / NIEHS NIH HHS / ES / P42 ES004705-220031
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Ferric Compounds; 0 / Phenols; 1K09F3G675 / ferric oxide; 7631-86-9 / Silicon Dioxide; BBX060AN9V / Hydrogen Peroxide
  • [Other-IDs] NLM/ NIHMS156855; NLM/ PMC2792909
  •  go-up   go-down


6. d'Amore F, Jantunen E, Relander T: Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how? Curr Hematol Malig Rep; 2009 Oct;4(4):236-44
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hemopoietic stem cell transplantation in T-cell malignancies: who, when, and how?
  • Only in recent years has there been a specific focus on the treatment of T-cell lymphomas in general and peripheral T-cell lymphomas (PTCLs) in particular.
  • In this context, the role of hemopoietic stem cell transplantation-primarily autologous but also allogeneic-has been investigated.
  • High-dose therapy with autologous stem cell transplantation (HDT/ASCT) proved feasible in both relapsed/refractory and previously untreated PTCL.
  • Reported outcomes have varied, often depending on the number of anaplastic large-cell lymphomas in the cohort.
  • In addition, retrospective results usually focus on patients undergoing transplantation, whereas the fraction of patients with primary refractory or early relapsing disease is best described in the intention-to-treat analysis of prospective trials.
  • This article reviews the most recent results of upfront HDT/ASCT consolidation in different subtypes of systemic PTCL.
  • The data on allogeneic stem cell transplantation are more limited, but promising results have recently been reported in the setting of relapsed or primary refractory disease.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Lymphoma, T-Cell / therapy

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] J Clin Oncol. 2004 Jun 1;22(11):2172-6 [15169805.001]
  • [Cites] Leuk Lymphoma. 2003 Dec;44(12):2163-4 [14959866.001]
  • [Cites] Br J Haematol. 2006 Apr;133(2):176-82 [16611309.001]
  • [Cites] Ann Oncol. 2008 May;19(5):958-63 [18303032.001]
  • [Cites] Ann Oncol. 2003 Nov;14(11):1673-6 [14581277.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):158-63 [2783376.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1783-90 [2585020.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Eur J Haematol. 2007 Apr;78(4):290-6 [17378891.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):711-6 [11360110.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Cancer. 2005 May 15;103(10):2091-8 [15816054.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):978-85 [12648067.001]
  • [Cites] Bone Marrow Transplant. 1999 Mar;23(5):437-42 [10100556.001]
  • [Cites] Bone Marrow Transplant. 2004 Mar;33(6):635-8 [15004538.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Bone Marrow Transplant. 2006 May;37(9):819-24 [16547486.001]
  • [Cites] Leuk Lymphoma. 2004 Nov;45(11):2261-7 [15512815.001]
  • [Cites] Blood. 1996 Feb 1;87(3):1045-55 [8562929.001]
  • [Cites] Bone Marrow Transplant. 2004 Feb;33(4):405-10 [14676776.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):106-13 [19029417.001]
  • [Cites] Ann Hematol. 2007 Jun;86(6):435-42 [17256144.001]
  • [Cites] J Clin Oncol. 2004 Jul 15;22(14):2826-34 [15254050.001]
  • [Cites] Curr Treat Options Oncol. 2004 Aug;5(4):289-303 [15233906.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3835-49 [10577857.001]
  • [Cites] Br J Haematol. 2000 Jun;109(4):736-42 [10929023.001]
  • [Cites] Haematologica. 2003 Dec;88(12):1372-7 [14687990.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • [Cites] Blood. 1997 Jun 15;89(12):4514-20 [9192775.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1):118-25 [19135950.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] Ann Oncol. 2004 Dec;15(12):1790-7 [15550584.001]
  • [Cites] Dig Liver Dis. 2007 Jul;39(7):634-41 [17531561.001]
  • [Cites] Ann Oncol. 1990;1(1):45-50 [1706610.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):443-50 [17589529.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):32-8 [17598836.001]
  • [Cites] Blood. 1990 Jul 15;76(2):424-31 [1973361.001]
  • [Cites] Bone Marrow Transplant. 2001 Jan;27(1):15-20 [11244433.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] Bone Marrow Transplant. 2007 Jan;39(2):71-87 [17213849.001]
  • [Cites] J Clin Oncol. 2008 Jan 10;26(2):218-24 [18182664.001]
  • [Cites] Ann Hematol. 2009 Feb;88(2):111-9 [18648812.001]
  • [Cites] Haematologica. 2003 Nov;88(11):1272-8 [14607756.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):441-6 [15160904.001]
  • [Cites] Bone Marrow Transplant. 2005 Aug;36(3):271-3 [15937499.001]
  • [Cites] Br J Haematol. 2007 Jan;136(1):111-3 [17116129.001]
  • [Cites] Bone Marrow Transplant. 1999 Jan;23(1):87-9 [10037056.001]
  • [Cites] Haematologica. 2007 Aug;92(8):1067-74 [17640855.001]
  • (PMID = 20425413.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 58
  •  go-up   go-down


7. Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, Lam CC, Leung AY, Tse E, Yau CC, Liang R, Kwong YL: Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol; 2005 Feb;16(2):206-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years.
  • BACKGROUND: Data on mature T-cell and natural killer (NK)-cell lymphomas diagnosed with the World Health Organization (WHO) classification scheme are scarce.
  • METHODS: Consecutive T-cell and NK-cell lymphomas classified according to the WHO scheme within 10 years in a Chinese population were reviewed.
  • RESULTS: There were 148 cases, constituting 16.6% (T-cell, n=90, 10.1%, NK-cell, n=58, 6.5%) of all non-Hodgkin lymphomas in this period.
  • There was a male predominance (male:female = 2.5), young age at diagnosis (median age 50 years, range 8-86) and frequent extranodal presentation.
  • Commonest T-cell lymphomas included anaplastic large cell lymphoma (ALCL, n=25, median age 35 years, nodal 60%, stage I/II 60%), peripheral T-cell lymphoma, unspecified (PTCL, n=24, median age 54 years, nodal 42%, stage I/II 42%), and angioimmunoblastic T-cell lymphoma (AILT, n=19, median age 67 years, nodal 95%, stage I/II 26%).
  • Overall frequencies of T-cell lymphomas were comparable to Western patients.
  • AILT, PTCL and ALCL were aggressive with a poor outcome.
  • NK-cell lymphomas were predominantly extranodal (96%) and aggressive, with a frequency much higher than Western patients.
  • CONCLUSIONS: The apparent high prevalence of T-cell and NK-cell lymphomas in the Chinese was due to more frequent NK-cell but not T-cell lymphomas.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15668271.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


8. Lu L, Ghose AK, Quail MR, Albom MS, Durkin JT, Holskin BP, Angeles TS, Meyer SL, Ruggeri BA, Cheng M: ALK mutants in the kinase domain exhibit altered kinase activity and differential sensitivity to small molecule ALK inhibitors. Biochemistry; 2009 Apr 28;48(16):3600-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Abnormal expression of constitutively active anaplastic lymphoma kinase (ALK) chimeric proteins in the pathogenesis of anaplastic large-cell lymphoma (ALCL) is well established.
  • Recent studies with small molecule kinase inhibitors have provided solid proof-of-concept validation that inhibition of ALK is sufficient to attenuate the growth and proliferation of ALK (+) ALCL cells.
  • NPM-ALK L182M, L182V, and L256M mutants displayed kinase activity in cells comparable to or higher than that of NPM-ALK wild type (WT) and rendered BaF3 cells into IL-3-independent growth, while NPM-ALK L182R, L256R, L256V, L256P, and L256Q displayed much weaker or little kinase activity in cells.
  • [MeSH-minor] Amino Acid Sequence. Animals. Cell Line. Humans. Lymphoma, Large-Cell, Anaplastic / genetics. Lymphoma, Large-Cell, Anaplastic / metabolism. Mice. Molecular Sequence Data. Molecular Structure. Neoplasm Transplantation. Receptor Protein-Tyrosine Kinases. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / metabolism. Sequence Alignment. Survival Rate

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19249873.001).
  • [ISSN] 1520-4995
  • [Journal-full-title] Biochemistry
  • [ISO-abbreviation] Biochemistry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


9. Sjostrom C, Seiler C, Crockett DK, Tripp SR, Elenitoba Johnson KS, Lim MS: Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma. Exp Hematol; 2007 Aug;35(8):1240-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Global proteome profiling of NPM/ALK-positive anaplastic large cell lymphoma.
  • OBJECTIVE: Constitutive overexpression of nucleophosmin/anaplastic lymphoma kinase (NPM/ALK) is a key oncogenic event in anaplastic large cell lymphomas (ALCL) that carry the t(2;5)(p23;q35) translocation.
  • Global proteomic analysis of NPM/ALK-positive ALCL would improve understanding of the disease pathogenesis and yield new candidate targets for novel treatment and diagnostic strategies.
  • MATERIALS AND METHODS: To comprehensively determine the inventory of proteins from NPM/ALK-positive ALCL SUDHL-1 cells, the membrane, cytoplasm, and nuclear subcellular fractions were resolved by one-dimensional sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and analyzed using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
  • Extensive annotation and systematic examination of the literature for information on 209 representative proteins indicated that 19.9% were reported to be expressed in T cells and 44.7% were reported to have important function in cancers, while only 4.3% were reported to be involved in ALCL pathogenesis.
  • CONCLUSION: We present an extensive catalog of proteins expressed by NPM/ALK-positive ALCL.
  • This study illustrates the potential for novel pathogenetic discovery in NPM/ALK-positive ALCL and the utility of combining cellular subfractionation, 1D SDS-PAGE, and LC-MS/MS for the comprehensive protein analysis of lymphoma.
  • [MeSH-major] Gene Expression Profiling. Lymphoma, Large B-Cell, Diffuse / genetics. Oncogene Proteins, Fusion / genetics. Protein-Tyrosine Kinases / genetics. Proteome
  • [MeSH-minor] Amino Acid Sequence. Cell Line, Tumor. Humans. Molecular Sequence Data. Neoplasm Proteins / genetics

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17560012.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / Oncogene Proteins, Fusion; 0 / Proteome; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  •  go-up   go-down


10. Hargittai M, Varga Z: Molecular constants of aluminum monohalides: caveats for computations of simple inorganic molecules. J Phys Chem A; 2007 Jan 11;111(1):6-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Structural parameters of the aluminum-monohalides, AlF, AlCl, AlBr, and AlI, have been calculated using the Gaussian 03 program package and different basis set combinations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17201381.001).
  • [ISSN] 1089-5639
  • [Journal-full-title] The journal of physical chemistry. A
  • [ISO-abbreviation] J Phys Chem A
  • [Language] eng
  • [Publication-type] Letter
  • [Publication-country] United States
  •  go-up   go-down


11. Voena C, Conte C, Ambrogio C, Boeri Erba E, Boccalatte F, Mohammed S, Jensen ON, Palestro G, Inghirami G, Chiarle R: The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration. Cancer Res; 2007 May 1;67(9):4278-86
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The tyrosine phosphatase Shp2 interacts with NPM-ALK and regulates anaplastic lymphoma cell growth and migration.
  • Anaplastic large cell lymphomas (ALCL) are mainly characterized by the reciprocal translocation t(2;5)(p23;q35) that involves the anaplastic lymphoma kinase (ALK) gene and generates the fusion protein NPM-ALK with intrinsic tyrosine kinase activity.
  • NPM-ALK triggers several signaling cascades, leading to increased cell growth, resistance to apoptosis, and changes in morphology and migration of transformed cells.
  • We found that NPM-ALK was able to bind Shp2 in coprecipitation experiments and to induce its phosphorylation in the tyrosine residues Y542 and Y580 both in HEK293 cells and ALCL cell lines.
  • In primary lymphomas, antibodies against the phosphorylated tyrosine Y542 of Shp2 mainly stained ALK-positive cells.
  • In ALCL cell lines, Shp2-constitutive phosphorylation was dependent on NPM-ALK, as it significantly decreased after short hairpin RNA (shRNA)-mediated NPM-ALK knock down.
  • Shp2 knock down by specific shRNA decreased the phosphorylation of extracellular signal-regulated kinase 1/2 and of the tyrosine residue Y416 in the activation loop of Src, resulting in impaired ALCL cell proliferation and growth disadvantage.
  • Finally, migration of ALCL cells was reduced by Shp2 shRNA.
  • These findings show a direct involvement of Shp2 in NPM-ALK lymphomagenesis, highlighting its critical role in lymphoma cell proliferation and migration.
  • [MeSH-major] Cell Movement / physiology. Intracellular Signaling Peptides and Proteins / metabolism. Lymphoma, Large B-Cell, Diffuse / enzymology. Lymphoma, Large B-Cell, Diffuse / pathology. Protein Tyrosine Phosphatases / metabolism. Protein-Tyrosine Kinases / metabolism
  • [MeSH-minor] Adaptor Proteins, Signal Transducing / metabolism. Amino Acid Sequence. Apoptosis / physiology. Cell Growth Processes / physiology. Down-Regulation. Enzyme Activation. GRB2 Adaptor Protein / metabolism. Humans. K562 Cells. Mass Spectrometry. Molecular Sequence Data. Phosphorylation. Protein Tyrosine Phosphatase, Non-Receptor Type 11. RNA, Small Interfering / genetics. SH2 Domain-Containing Protein Tyrosine Phosphatases. Transfection

  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cancer Res. 2016 Mar 15;76(6):1669 [26979794.001]
  • (PMID = 17483340.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01-CA64033
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / GAB2 protein, human; 0 / GRB2 Adaptor Protein; 0 / Intracellular Signaling Peptides and Proteins; 0 / RNA, Small Interfering; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.1.3.48 / PTPN11 protein, human; EC 3.1.3.48 / Protein Tyrosine Phosphatase, Non-Receptor Type 11; EC 3.1.3.48 / Protein Tyrosine Phosphatases; EC 3.1.3.48 / SH2 Domain-Containing Protein Tyrosine Phosphatases
  •  go-up   go-down


12. Delsol G: [Molecular abnormalities in lymphomas]. Bull Cancer; 2010 Nov;97(11):1347-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular abnormalities in lymphomas].
  • Numerous molecular abnormalities have been described in lymphomas.
  • They also shed some light on the underlying molecular mechanisms involved in lymphomas.
  • In some lymphomas, genetic abnormalities are responsible for the expression of an abnormal protein (e.g. tyrosine-kinase, transcription factor) detectable by immunohistochemistry.
  • In the present review, molecular abnormalities observed in the most frequent B, T or NK cell lymphomas are discussed.
  • In the broad spectrum of diffuse large B-cell lymphomas microarray analysis shows mostly two subgroups of tumors, one with gene expression signature corresponding to germinal center B-cell-like (GCB: CD10+, BCL6 [B-Cell Lymphoma 6]+, centerine+, MUM1-) and a subgroup expressing an activated B-cell-like signature (ABC: CD10-, BCL6-, centerine-, MUM1+).
  • Among other B-cell lymphomas with well characterized molecular abnormalies are follicular lymphoma (BCL2 deregulation), MALT lymphoma (Mucosa Associated Lymphoid Tissue) [API2-MALT1 (mucosa-associated-lymphoid-tissue-lymphoma-translocation-gene1) fusion protein or deregulation BCL10, MALT1, FOXP1.
  • MALT1 transcription factors], mantle cell lymphoma (cycline D1 [CCND1] overexpression) and Burkitt lymphoma (c-Myc expression).
  • Except for ALK (anaplastic lymphoma kinase)-positive anaplastic large cell lymphoma, well characterized molecular anomalies are rare in lymphomas developed from T or NK cells.
  • Peripheral T cell lymphomas not otherwise specified are a heterogeneous group of tumors with frequent but not recurrent molecular abnormalities.
  • In angio-immunoblastic T-cell lymphomas molecular abnormalities are found in follicular helper T-cell (TFH) that express some distinctive markers such as CD10, PD-1, CXCR5 and the CXCL13 chemokine.
  • ALK-positive anaplastic large cell lymphoma is a paradigme of T-cell lymphoma since it is associated with an X-ALK oncogenic fusion protein due to a translocation involving ALK gene at 2p23.
  • Lastly several lymphomas are associated with infectious agents that play a direct (EB virus, HTLV1) or indirect role (e.g.
  • Helicobacter pylori in MALT lymphoma) in lymphomagenesis.
  • [MeSH-major] Gene Amplification / genetics. Genes, Tumor Suppressor. Lymphoma / genetics. Mutation / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Gene Deletion. Gene Expression Regulation, Neoplastic / genetics. Genetic Techniques. Humans. Lymphoma, B-Cell / genetics. Lymphoma, B-Cell / metabolism. Lymphoma, T-Cell / genetics. Lymphoma, T-Cell / metabolism. Neoplasm Proteins / metabolism


13. Farkash EA, Ferry JA, Harris NL, Hochberg EP, Takvorian RW, Zuckerman DS, Sohani AR: Rare lymphoid malignancies of the breast: a report of two cases illustrating potential diagnostic pitfalls. J Hematop; 2009;2(4):237-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Breast involvement by lymphoma is uncommon and poses challenges in diagnosis.
  • Lymphomas may clinically, radiologically, and morphologically mimic both benign and neoplastic conditions.
  • The first case, ALK-negative anaplastic large-cell lymphoma involving a seroma associated with a breast implant, is an emerging clinicopathologic entity.
  • Anaplastic large-cell lymphoma has been identified in association with breast implants and seroma formation relatively recently.
  • The second case, hairy cell leukemia involving the breast and ipsilateral axillary sentinel lymph node, is, to our knowledge, the first reported case of hairy cell leukemia involving the breast at the time of diagnosis.
  • While a localized bone lesion was present at time of diagnosis, bone marrow involvement was relatively mild in comparison to that seen in the breast and lymph node.
  • In the first case, lymphoma occurred in a clinical setting where malignancy was unsuspected, highlighting the importance of careful morphologic evaluation of paucicellular samples, as well as awareness of rare clinicopathologic entities, in avoiding a misdiagnosis of a benign inflammatory infiltrate.
  • In the second case, the lymphoid neoplasm exhibited classic morphologic and immunophenotypic features, but presented at an unusual site of involvement.
  • Knowledge of the patient's concurrent diagnosis of hairy cell leukemia involving the bone marrow and bone helped avoid a misdiagnosis of carcinoma rather than lymphoma.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Acta Medica (Hradec Kralove). 2003;46(4):175-7 [14965169.001]
  • [Cites] Ann Hematol. 2003 Jul;82(7):397-404 [12764549.001]
  • [Cites] Hematol Oncol Clin North Am. 2006 Oct;20(5):1065-73 [16990107.001]
  • [Cites] Ann Plast Surg. 2007 Jul;59(1):56-7 [17589261.001]
  • [Cites] Mod Pathol. 2008 Apr;21(4):455-63 [18223553.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Am J Surg Pathol. 2008 Aug;32(8):1265-8 [18594466.001]
  • [Cites] Am J Surg Pathol. 2008 Sep;32(9):1299-309 [18636016.001]
  • [Cites] Cancer. 2008 Oct 1;113(7):1511-20 [18704988.001]
  • [Cites] JAMA. 2008 Nov 5;300(17):2030-5 [18984890.001]
  • [Cites] Cancer. 1979 Apr;43(4):1339-49 [445334.001]
  • [Cites] Br J Cancer. 1989 Oct;60(4):605-9 [2803932.001]
  • [Cites] J Clin Oncol. 1988 Aug;6(8):1280-4 [3411340.001]
  • [Cites] Cancer. 1972 Jun;29(6):1705-12 [4555557.001]
  • [Cites] Ann Intern Med. 1973 Jan;78(1):113-8 [4565899.001]
  • [Cites] Cancer. 1974 May;33(5):1399-410 [4823484.001]
  • [Cites] Semin Oncol. 1984 Dec;11(4):370-80 [6505704.001]
  • [Cites] Plast Reconstr Surg. 1994 Oct;94(5):628-33; discussion 634-6 [7938285.001]
  • [Cites] Am J Surg Pathol. 1996 Apr;20(4):505-7 [8604821.001]
  • [Cites] Plast Reconstr Surg. 1997 Aug;100(2):554-5 [9252643.001]
  • [Cites] Semin Oncol. 1999 Jun;26(3):357-64 [10375092.001]
  • [Cites] J Clin Pathol. 2000 Jun;53(6):445-50 [10911802.001]
  • [Cites] Cancer Causes Control. 2000 Oct;11(9):819-27 [11075871.001]
  • [Cites] Leuk Lymphoma. 2002 Jan;43(1):115-9 [11908714.001]
  • [Cites] Arch Pathol Lab Med. 2003 Mar;127(3):e115-8 [12653596.001]
  • [Cites] Leukemia. 2003 Dec;17(12):2257-317 [14671650.001]
  • [Cites] Leuk Lymphoma. 2003 Jul;44(7):1173-8 [12916870.001]
  • [Cites] Virchows Arch. 2006 Nov;449(5):561-4 [16983530.001]
  • (PMID = 20309431.001).
  • [ISSN] 1865-5785
  • [Journal-full-title] Journal of hematopathology
  • [ISO-abbreviation] J Hematop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2798933
  • [Keywords] NOTNLM ; Anaplastic large cell lymphoma / Anaplastic lymphoma kinase / Breast / Breast implant / Hairy cell leukemia / Primary breast lymphoma / Seroma / T-cell neoplasm
  •  go-up   go-down


14. Cwiklińska M, Czogała M, Balwierz W, Hnatko-Kołacz M, Moryl-Bujakowska A, Malinowska I, Sładek M, Wieczorek M, Fyderek K, Matysiak M, Rygielska M, Sierhej I: [Hemophagocytic syndrome in children with different underlying conditions]. Przegl Lek; 2010;67(6):430-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In 3 cases HS was associated with infections (EBV, CMV, Bacillus Calmette Guerin - BCG), in 1 child with non-Hodgkin anaplastic large cell lymphoma (ALCL), in 1 patients probably with side effect of antiepileptic drug.
  • Patient with ALCL was treated with chemotherapy and allogeneic stem cell transplantation.
  • Four patients are alive, 2 died because of HS, child with ALCL died because of generalized infection in peritrans-plantation period.
  • In case of prolonged fever, splenomegaly and cytopenia diagnosis of HS should be considered.
  • Following tests are recommended: complete blood count, ferritin, triglycerides, fibrinogen, bone marrow aspiration and NK cell assessment.
  • Early diagnosis of HS and underlying condition is crucial to start lifesaving therapy.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / diagnosis. Lymphohistiocytosis, Hemophagocytic / etiology
  • [MeSH-minor] Adolescent. Anticonvulsants / adverse effects. Child. Child, Preschool. Female. Humans. Infant. Infant, Newborn. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / diagnosis. Magnetic Resonance Imaging. Male. Virus Diseases / complications. Virus Diseases / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21344776.001).
  • [ISSN] 0033-2240
  • [Journal-full-title] Przegla̧d lekarski
  • [ISO-abbreviation] Prz. Lek.
  • [Language] pol
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / Anticonvulsants
  •  go-up   go-down


15. Bonvini P, Zorzi E, Mussolin L, Monaco G, Pigazzi M, Basso G, Rosolen A: The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity. Haematologica; 2009 Jul;94(7):944-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of the cyclin-dependent kinase inhibitor flavopiridol on anaplastic large cell lymphoma cells and relationship with NPM-ALK kinase expression and activity.
  • BACKGROUND: The loss of cell cycle regulation due to abnormal function of cyclin-dependent kinases (cdk) occurs in tumors and leads to genetic instability of chemotherapy-resistant cells.
  • In this study, we investigated the effect of the cdk inhibitor flavopiridol in anaplastic large cell lymphomas, in which unrestrained proliferation depends on NPM-ALK tyrosine kinase activity.
  • DESIGN AND METHODS: Effects of flavopiridol were examined in ALK-positive and -negative anaplastic large cell lymphoma cells by means of immunoblotting and immunofluorescence analyses to assess cdk expression and activity, quantitative real time reverse transcriptase polymerase chain reaction to measure drug-induced changes in transcription, and FACS analyses to monitor changes in proliferation and survival.
  • RESULTS: Treatment with flavopiridol resulted in growth inhibition of anaplastic large cell lymphoma cells, along with accumulation of subG(1) cells and disappearance of S phase without cell cycle arrest.
  • This correlated with induction of cell death through rapid mitochondrial damage, inhibition of DNA synthesis, and down-regulation of anti-apoptotic proteins and transcripts.
  • Notably, flavopiridol was less active in ALK-positive cells, as apoptosis was observed at higher concentrations and later time points, and resistance to treatment was observed in cells maintaining NPM-ALK signaling.
  • NPM-ALK inhibition affected proliferation but not survival of anaplastic large cell lym-phoma cells, whereas it resulted in a dramatic increase in apoptosis when combined with flavopiridol.
  • CONCLUSIONS: This work provides the first demonstration that targeting cdk is effective against anaplastic large cell lymphoma cells, and proves the critical role of NPM-ALK in the regulation of responsiveness of tumor cells with cdk dysregulation.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Flavonoids / pharmacology. Gene Expression Regulation, Neoplastic. Lymphoma, Large-Cell, Anaplastic / drug therapy. Piperidines / pharmacology. Protein-Tyrosine Kinases / biosynthesis
  • [MeSH-minor] Apoptosis. Bromodeoxyuridine / pharmacology. Cell Cycle. Cell Separation. Cell Survival. Dose-Response Relationship, Drug. Humans. Reverse Transcriptase Polymerase Chain Reaction. Subcellular Fractions. Time Factors


16. Pulford K, Roberton HM, Jones M: Antibody techniques used in the study of anaplastic lymphoma kinase-positive ALCL. Methods Mol Med; 2005;115:271-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antibody techniques used in the study of anaplastic lymphoma kinase-positive ALCL.
  • The availability of suitable reagents for routine diagnostic use has revolutionized the study of leukemia and lymphoma pathology.
  • The use of antibodies specific for anaplastic lymphoma kinase (ALK) protein has permitted the identification of the tumor entity ALK-positive from the poorly defined morphological category of anaplastic large cell lymphoma.
  • This chapter describes the use of antibodies in both immunolabeling (immunocytochemical and immunofluorescence) procedures and in biochemical procedures in the study of ALK-positive ALCL.
  • [MeSH-major] Antibodies, Monoclonal / immunology. Antibodies, Neoplasm / immunology. Blotting, Western / methods. Lymphoma, Large-Cell, Anaplastic / diagnosis. Protein-Tyrosine Kinases / immunology. Receptor Protein-Tyrosine Kinases / immunology

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15998974.001).
  • [ISSN] 1543-1894
  • [Journal-full-title] Methods in molecular medicine
  • [ISO-abbreviation] Methods Mol. Med.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Neoplasm; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


17. Watanabe N, Kato H, Murakami J, Shimizu M, Noguchi K, Kamisaki Y, Matsunari I, Seto H: FDG-PET imaging in cutaneous anaplastic large cell lymphoma. Clin Nucl Med; 2006 Sep;31(9):564-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET imaging in cutaneous anaplastic large cell lymphoma.
  • [MeSH-major] Fluorodeoxyglucose F18. Lymphoma, Large B-Cell, Diffuse / diagnosis. Lymphoma, Large B-Cell, Diffuse / radionuclide imaging. Positron-Emission Tomography / methods. Radiopharmaceuticals

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16921287.001).
  • [ISSN] 0363-9762
  • [Journal-full-title] Clinical nuclear medicine
  • [ISO-abbreviation] Clin Nucl Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radiopharmaceuticals; 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


18. Sanap SP, Ghosh S, Jabgunde AM, Pinjari RV, Gejji SP, Singh S, Chopade BA, Dhavale DD: Synthesis, computational study and glycosidase inhibitory activity of polyhydroxylated conidine alkaloids--a bicyclic iminosugar. Org Biomol Chem; 2010 Jul 21;8(14):3307-15
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Individual treatment of 3a/3b with the Mukaiyama reagent afforded sugar beta-lactams 4a/4b that on reduction with LiAlH(4)/AlCl(3) gave azetidines 5a/5b with a sugar appendage.
  • Compound 1d was found to be a moderate inhibitor of glycosidases while 1e was noticed to be a good inhibitor of alpha-mannosidase and a moderate inhibitor of other glycosidases.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20517582.001).
  • [ISSN] 1477-0539
  • [Journal-full-title] Organic & biomolecular chemistry
  • [ISO-abbreviation] Org. Biomol. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkaloids; 0 / Enzyme Inhibitors; 0 / Imino Sugars; 0 / Polymers; 87323-81-7 / conidine; EC 3.2.1.- / Glycoside Hydrolases
  •  go-up   go-down


19. García-Castro M, Martín A, Mena M, Yélamos C: Molecular nitrides with titanium and Group 13-15 elements. Chemistry; 2009 Jul 20;15(29):7180-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Complexes 3 and 4 were also obtained by treatment of 1 with the trialkyl derivatives [M(CH(2)SiMe(3))(3)] (M = Ga, In) at high temperatures.
  • The analogous reaction of 1 with [{Ga(NMe(2))(3)}(2)] at 110 degrees C leads to [{Ga(mu(3)-N)(2)(mu(3)-NH)Ti(3)(eta(5)-C(5)Me(5))(3)(mu(3)-N)}(2)] (5), in which two [GaTi(3)N(4)] cube-type moieties are linked through a gallium-gallium bond.
  • Complex 1 reacts with one equivalent of germanium, tin, or lead bis(trimethylsilyl)amido derivatives [M{N(SiMe(3))(2)}(2)] in toluene at room temperature to give cube-type complexes [M{(mu(3)-N)(2)(mu(3)-NH)Ti(3)(eta(5)-C(5)Me(5))(3)(mu(3)-N)}] [M = Ge (6), Sn (7), Pb (8)].
  • Treatment of 1 with [AlCl(2){N(SiMe(3))(2)}(OEt(2))] affords the precipitation of the singular aluminum-titanium square-pyramidal aggregate [{{(Me(3)Si)(2)N}Cl(3)Al(2)}(mu(3)-N)(mu(3)-NH)(2){Ti(3)(eta(5)-C(5)Me(5))(3)(mu-Cl)(mu(3)-N)}] (14).
  • The X-ray crystal structures of 5, 11, 13, 14, and [AlCl{N(SiMe(3))(2)}(2)] were determined.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19544507.001).
  • [ISSN] 1521-3765
  • [Journal-full-title] Chemistry (Weinheim an der Bergstrasse, Germany)
  • [ISO-abbreviation] Chemistry
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


20. Borchmann P: CD30+ diseases: anaplastic large-cell lymphoma and lymphomatoid papulosis. Cancer Treat Res; 2008;142:349-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30+ diseases: anaplastic large-cell lymphoma and lymphomatoid papulosis.
  • [MeSH-major] Antigens, CD30 / metabolism. Lymphoma, Large-Cell, Anaplastic. Lymphomatoid Papulosis. Skin Neoplasms


21. Fatusi O, Gbolahan O, Owotade F, Rotimi O, Edward S, Adelusola K: Anaplastic large cell lymphoma: case report and literature review. J Oral Maxillofac Surg; 2010 Apr;68(4):884-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma: case report and literature review.
  • [MeSH-major] Facial Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19954878.001).
  • [ISSN] 1531-5053
  • [Journal-full-title] Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  • [ISO-abbreviation] J. Oral Maxillofac. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 25
  •  go-up   go-down


22. Rupani A, Modi C, Desai S, Rege J: Primary anaplastic large cell lymphoma of central nervous system--a case report. J Postgrad Med; 2005 Oct-Dec;51(4):326-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary anaplastic large cell lymphoma of central nervous system--a case report.
  • Central nervous system (CNS) involvement is extremely rare in anaplastic large cell lymphoma (ALCL).
  • Primary ALCL of CNS on radiology is often misdiagnosed as tuberculosis.
  • We report a fatal case of primary ALCL of CNS in a 17 year old male.
  • Biopsy showed large pleomorphic cells.
  • Immunohistochemical stains showed positivity for CD30, CD43, EMA and ALK-1.
  • Hence a high level of suspicion is essential for early diagnosis and for instituting appropriate treatment.
  • [MeSH-major] Central Nervous System Neoplasms / diagnosis. Lymphoma, Large B-Cell, Diffuse / diagnosis
  • [MeSH-minor] Adolescent. Diagnostic Errors. Fatal Outcome. Humans. Magnetic Resonance Imaging. Male. Tuberculosis / diagnosis


23. Rust R, Visser L, van der Leij J, Harms G, Blokzijl T, Deloulme JC, van der Vlies P, Kamps W, Kok K, Lim M, Poppema S, van den Berg A: High expression of calcium-binding proteins, S100A10, S100A11 and CALM2 in anaplastic large cell lymphoma. Br J Haematol; 2005 Dec;131(5):596-608
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High expression of calcium-binding proteins, S100A10, S100A11 and CALM2 in anaplastic large cell lymphoma.
  • Anaplastic large cell lymphomas (ALCL) are characterised by the presence of CD30-positive large cells, which usually are of T-cell type.
  • Based on the presence or absence of translocations involving the anaplastic lymphoma kinase (ALK) locus, ALCL cases can be divided into two groups.
  • To gain more insight in the biology of ALCL, we applied serial analysis of gene expression (SAGE) on the Karpas299 cell line and identified 25 up- and 19 downregulated genes.
  • Quantitative reverse transcription polymerase chain reaction on 5 ALCL cell lines and 12 ALCL tissues confirmed the SAGE data for 13 out of 14 up- and one out of four downregulated genes.
  • Immunohistochemical staining confirmed the presence of S100A10, a calcium-binding protein, in three out of five ALK+ and all 7 ALK- ALCL cases.
  • S100A11 staining was confirmed in all ALK+ and six of seven ALK- ALCL cases.
  • Three of the upregulated genes represented calcium-binding proteins, which suggest that altered intracellular signaling might be associated with the oncogenesis of ALCL.
  • [MeSH-major] Annexin A2 / genetics. Calcium Signaling / genetics. Calmodulin / genetics. Gene Expression Regulation, Neoplastic. Lymphoma, Large B-Cell, Diffuse / genetics. S100 Proteins / genetics
  • [MeSH-minor] CD4-Positive T-Lymphocytes / metabolism. Cell Line, Tumor. Cells, Cultured. Down-Regulation. Galectin 1 / analysis. Galectin 1 / genetics. Gene Expression Profiling. Humans. Immunohistochemistry / methods. Membrane Proteins / genetics. Oligonucleotide Array Sequence Analysis. Reverse Transcriptase Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16351635.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Annexin A2; 0 / CALM2 protein, human; 0 / Calmodulin; 0 / Galectin 1; 0 / Membrane Proteins; 0 / S100 Proteins; 0 / S100 calcium binding protein A10; 146909-89-9 / S100A11 protein, human; 179801-28-6 / LAPTM5 protein, human
  •  go-up   go-down


24. Slack GW, Ferry JA, Hasserjian RP, Sohani AR, Longtine JA, Harris NL, Zukerberg LR: Lymphocyte depleted Hodgkin lymphoma: an evaluation with immunophenotyping and genetic analysis. Leuk Lymphoma; 2009 Jun;50(6):937-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphocyte depleted Hodgkin lymphoma: an evaluation with immunophenotyping and genetic analysis.
  • Lymphocyte depleted classical Hodgkin lymphoma (LDHL) is a vanishing category of classical Hodgkin lymphoma (CHL); many cases previously placed in this category are now recognised as diffuse large B-cell lymphoma (DLBCL), anaplastic large-cell lymphoma (ALCL), or nodular sclerosis CHL with lymphocyte depletion.
  • In addition, the recent recognition of high grade B-cell lymphomas intermediate between DLBCL and CHL (grey-zone lymphomas) raises the question of whether LDHL exists at all as a category of CHL.
  • In three cases the tumors had a more diffuse fibrotic appearance, while in five cases they appeared reticular and anaplastic.
  • Neoplastic cells in all cases expressed CD30, CD15, fascin, weak PAX5 and MUM-1 and lacked CD45, Alk-1, EMA, CD3, CD68, Mart-1 and cytokeratin.
  • Four cases were positive for EBV.
  • The combined morphologic, immunophenotypic and molecular genetic features of this group of cases distinguish LDHL from other disease entities, including grey-zone lymphomas.
  • [MeSH-major] Hodgkin Disease / pathology. Lymphocytes / pathology. Reed-Sternberg Cells / pathology
  • [MeSH-minor] Adult. Aged. Antigens, CD15 / analysis. Antigens, CD30 / analysis. B-Cell-Specific Activator Protein / analysis. Carrier Proteins / analysis. Female. Gene Rearrangement. Humans. Immunoglobulin Heavy Chains / genetics. Immunohistochemistry. Interferon Regulatory Factors / analysis. Male. Microfilament Proteins / analysis. Middle Aged. Polymerase Chain Reaction


25. Blume JE, Stoll HL, Cheney RT: Treatment of primary cutaneous CD30+ anaplastic large cell lymphoma with intralesional methotrexate. J Am Acad Dermatol; 2006 May;54(5 Suppl):S229-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary cutaneous CD30+ anaplastic large cell lymphoma with intralesional methotrexate.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Lymphoma, Large-Cell, Anaplastic / drug therapy. Methotrexate / administration & dosage

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16631947.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


26. Yamamoto R, Nishikori M, Tashima M, Sakai T, Ichinohe T, Takaori-Kondo A, Ohmori K, Uchiyama T: B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma. Cancer Sci; 2009 Nov;100(11):2093-100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B7-H1 expression is regulated by MEK/ERK signaling pathway in anaplastic large cell lymphoma and Hodgkin lymphoma.
  • We examined B7-H1 expression in anaplastic large cell lymphoma (ALCL) and Hodgkin lymphoma (HL) and found that it was constitutively expressed in both clinical samples and cell lines.
  • In anaplastic lymphoma kinase-positive (ALK(+)) ALCL cells, B7-H1 expression was suppressed by the blocking of extracellular signal-regulated kinase (ERK) signaling and upregulated by the augmentation of ERK activity by phorbol 13-myristate 12-acetate stimulation, suggesting that B7-H1 expression is regulated by ERK signaling pathway in ALCL.
  • ERK is one of the downstream mediators of nucleophosmin (NPM)/ALK signaling in ALK(+)ALCL, and pharmacological inhibition of ALK was shown to dephosphorylate ERK and down-regulate B7-H1.
  • The involvement of NPM/ALK in B7-H1 expression was also demonstrated by introducing the construct into human non-ALCL lymphoid cell lines, which resulted in B7-H1 expression.
  • These results suggest that B7-H1 expression is controlled by common ERK signaling pathways in ALCL and HL cells.
  • [MeSH-major] Antigens, CD / analysis. Extracellular Signal-Regulated MAP Kinases / physiology. Hodgkin Disease / metabolism. Lymphoma, Large-Cell, Anaplastic / metabolism. MAP Kinase Signaling System / physiology. Mitogen-Activated Protein Kinase Kinases / physiology
  • [MeSH-minor] Antigens, CD274. Cell Line, Tumor. Humans. Protein-Tyrosine Kinases / physiology. STAT3 Transcription Factor / physiology


27. Kuperman T, Wexler ID, Shoseyov D, Weintraub M, Revel-Vilk S, Kerem E: Plastic bronchitis caused by neoplastic infiltrates in a child. Pediatr Pulmonol; 2006 Sep;41(9):893-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An extensive workup revealed an anaplastic large-cell lymphoma with neoplastic cells, found in both a biopsied lymph node and pleural fluid aspirate.
  • Neoplastic infiltration of the bronchi should be considered in the differential diagnosis of disease entities causing plastic bronchitis in children.
  • [MeSH-major] Bronchitis / etiology. Bronchitis / pathology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / pathology

  • MedlinePlus Health Information. consumer health - Acute Bronchitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16779857.001).
  • [ISSN] 8755-6863
  • [Journal-full-title] Pediatric pulmonology
  • [ISO-abbreviation] Pediatr. Pulmonol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Gorrepati EA, Wongthahan P, Raha S, Fogler HS: Silica precipitation in acidic solutions: mechanism, pH effect, and salt effect. Langmuir; 2010 Jul 6;26(13):10467-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The effect of salt was also studied by adding 1 M chloride salts to the solutions; it was found that salts accelerated both particle formation and growth rates in the order: AlCl(3) > CaCl(2) > MgCl(2) > NaCl > CsCl > no salt.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20536253.001).
  • [ISSN] 1520-5827
  • [Journal-full-title] Langmuir : the ACS journal of surfaces and colloids
  • [ISO-abbreviation] Langmuir
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Salts; 0 / Solutions; 7631-86-9 / Silicon Dioxide
  •  go-up   go-down


29. Yin L, Mano J, Wang S, Tsuji W, Tanaka K: The involvement of lipid peroxide-derived aldehydes in aluminum toxicity of tobacco roots. Plant Physiol; 2010 Mar;152(3):1406-17
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Transgenic tobacco (Nicotiana tabacum) overexpressing Arabidopsis (Arabidopsis thaliana) 2-alkenal reductase (AER-OE plants), wild-type SR1, and an empty vector-transformed control line (SR-Vec) were exposed to AlCl(3) on their roots.
  • Compared with the two controls, AER-OE plants suffered less retardation of root elongation under AlCl(3) treatment and showed more rapid regrowth of roots upon Al removal.
  • Under AlCl(3) treatment, the roots of AER-OE plants accumulated Al and H(2)O(2) to the same levels as did the sensitive controls, while they accumulated lower levels of aldehydes and suffered less cell death than SR1 and SR-Vec roots.
  • In SR1 roots, AlCl(3) treatment markedly increased the contents of the highly reactive 2-alkenals acrolein, 4-hydroxy-(E)-2-hexenal, and 4-hydroxy-(E)-2-nonenal and other aldehydes such as malondialdehyde and formaldehyde.
  • [MeSH-minor] Arabidopsis / enzymology. Arabidopsis Proteins / metabolism. Cell Death. Hydrogen Peroxide / metabolism. Lipid Peroxidation. Oxidative Stress. Plants, Genetically Modified / drug effects. Plants, Genetically Modified / metabolism

  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • Hazardous Substances Data Bank. HYDROGEN PEROXIDE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plant Physiol. 2000 Mar;122(3):657-65 [10712528.001]
  • [Cites] Planta. 2009 Sep;230(4):639-48 [19578873.001]
  • [Cites] Plant J. 2000 Nov;24(4):437-46 [11115125.001]
  • [Cites] Plant Physiol. 2001 Jan;125(1):199-208 [11154329.001]
  • [Cites] IUBMB Life. 2000 Oct-Nov;50(4-5):315-21 [11327326.001]
  • [Cites] Plant Physiol. 2002 Jan;128(1):63-72 [11788753.001]
  • [Cites] J Biol Chem. 2002 Nov 8;277(45):42663-8 [12213810.001]
  • [Cites] Anal Chem. 2002 Dec 15;74(24):6298-304 [12510752.001]
  • [Cites] Plant Cell Physiol. 2002 Dec;43(12):1445-55 [12514241.001]
  • [Cites] Plant J. 2003 Aug;35(4):452-64 [12904208.001]
  • [Cites] J Inorg Biochem. 2003 Sep 15;97(1):59-68 [14507461.001]
  • [Cites] J Exp Bot. 2004 Jan;55(394):1-10 [14645387.001]
  • [Cites] Curr Opin Plant Biol. 2004 Aug;7(4):441-8 [15231268.001]
  • [Cites] Annu Rev Plant Biol. 2004;55:459-93 [15377228.001]
  • [Cites] Z Naturforsch C. 1975 Jul-Aug;30(4):466-73 [241172.001]
  • [Cites] Anal Biochem. 1976 May 7;72:248-54 [942051.001]
  • [Cites] Free Radic Biol Med. 1991;11(1):81-128 [1937131.001]
  • [Cites] Plant Physiol. 1996 Mar;110(3):743-51 [8819866.001]
  • [Cites] Mutagenesis. 1998 May;13(3):287-305 [9643589.001]
  • [Cites] Prog Lipid Res. 1998 May;37(1):33-72 [9764311.001]
  • [Cites] Biochem J. 2005 May 1;387(Pt 3):865-70 [15689186.001]
  • [Cites] Plant Physiol. 2005 Dec;139(4):1773-83 [16299173.001]
  • [Cites] Crit Rev Toxicol. 2005 Aug;35(7):609-62 [16417045.001]
  • [Cites] Plant Physiol. 2006 Jun;141(2):312-22 [16760481.001]
  • [Cites] Plant Cell Environ. 2006 Jun;29(6):1033-48 [17080931.001]
  • [Cites] Plant Cell Environ. 2006 Jul;29(7):1309-18 [17080952.001]
  • [Cites] J Exp Bot. 2007;58(3):497-506 [17150990.001]
  • [Cites] Annu Rev Plant Biol. 2007;58:459-81 [17288534.001]
  • [Cites] New Phytol. 2008;177(1):155-66 [18028301.001]
  • [Cites] J Biol Chem. 2007 Dec 28;282(52):37436-47 [17947244.001]
  • [Cites] Plant Cell Rep. 2008 May;27(5):951-61 [18204843.001]
  • [Cites] Ecotoxicol Environ Saf. 2008 Jun;70(2):300-10 [18068230.001]
  • [Cites] Plant Physiol. 2008 Jun;147(2):528-42 [18441225.001]
  • [Cites] J Agric Food Chem. 2008 Oct 22;56(20):9676-84 [18803390.001]
  • [Cites] Plant Cell Environ. 2009 Jan;32(1):31-45 [19076530.001]
  • [Cites] FEBS Lett. 2000 Sep 15;481(2):117-21 [10996308.001]
  • (PMID = 20023145.001).
  • [ISSN] 1532-2548
  • [Journal-full-title] Plant physiology
  • [ISO-abbreviation] Plant Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aldehydes; 0 / Arabidopsis Proteins; 0 / Lipid Peroxides; BBX060AN9V / Hydrogen Peroxide; CPD4NFA903 / Aluminum
  • [Other-IDs] NLM/ PMC2832258
  •  go-up   go-down


30. Thakuria M, Agarwal S, Saffold OE, Jaworsky C: Fulminant cutaneous eruption in a 51-year-old man. Primary cutaneous anaplastic large cell lymphoma (C-ALCL). Arch Dermatol; 2007 Feb;143(2):255-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fulminant cutaneous eruption in a 51-year-old man. Primary cutaneous anaplastic large cell lymphoma (C-ALCL).
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / pathology. Skin Neoplasms / pathology


31. Davis AK, Cole-Sinclair M, Russell P: Anaplastic large cell lymphoma presenting with paraneoplastic pemphigus. J Clin Pathol; 2007 Jan;60(1):108-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma presenting with paraneoplastic pemphigus.
  • [MeSH-major] Autoimmune Diseases / etiology. Lymphoma, Large-Cell, Anaplastic / complications. Paraneoplastic Syndromes / etiology. Pemphigus / etiology


32. de Leval L, Gaulard P: Pathobiology and molecular profiling of peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program; 2008;:272-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pathobiology and molecular profiling of peripheral T-cell lymphomas.
  • Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of rare diseases, usually manifesting clinical aggressiveness.
  • Angioimmunoblastic T-cell lymphoma (AITL) comprises CD4+ CXCL13+ neoplastic cells displaying overlapping immunophenotypical and molecular features with normal follicular helper T cells.
  • This derivation might account for the presence of a prominent non-neoplastic component in AITL tissues and the clinical manifestations of the disease reflective of an immunological dysfunction.
  • ALK+ anaplastic large cell lymphoma (ALCL), defined by ALK gene translocation with various gene partners, is composed of CD30+ ALK+ cells with a cytotoxic phenotype and usually carries a good prognosis.
  • ALK- ALCL, now considered as a distinct disease entity, is morphologically and immunophenotypically similar to ALK+ ALCL, except for ALK expression, but has distinctive molecular features.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074096.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Yao C, Rahmanzadeh R, Endl E, Zhang Z, Gerdes J, Hüttmann G: Elevation of plasma membrane permeability by laser irradiation of selectively bound nanoparticles. J Biomed Opt; 2005 Nov-Dec;10(6):064012
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We demonstrate that the system enables molecules to penetrate impermeable cell membranes.
  • Laser light at 532 nm is used to irradiate conjugates of colloidal gold, which are delivered by antibodies to the plasma membrane of the Hodgkin's disease cell line L428 and/or the human large-cell anaplastic lymphoma cell line Karpas 299.
  • The fraction of transiently permeabilized and then resealed cells is affected by the laser parameter, the gold concentration, and the membrane protein of the different cell lines to which the nanoparticles are bound.
  • Furthermore, a dependence on particle size is found for these interactions in the different cell lines.
  • [MeSH-major] Cell Membrane Permeability / physiology. Cell Membrane Permeability / radiation effects. Drug Delivery Systems / methods. Fluoresceins / pharmacokinetics. Lasers. Lymphoma / metabolism. Nanostructures
  • [MeSH-minor] Biopolymers / pharmacokinetics. Cell Line, Tumor. Humans


34. Pavlovkin J, Pal'ove-Balang P, Kolarovic L, Zelinová V: Growth and functional responses of different cultivars of Lotus corniculatus to aluminum and low pH stress. J Plant Physiol; 2009 Sep 15;166(14):1479-87
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Treatment with 250microM of AlCl(3) (pH 4) resulted in rapid membrane depolarization.
  • [MeSH-minor] Cell Respiration / drug effects. Hydrogen-Ion Concentration. Membrane Potentials / drug effects. Plant Roots / drug effects. Plant Roots / growth & development. Plant Roots / metabolism. Potassium / metabolism

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. POTASSIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19409655.001).
  • [ISSN] 1618-1328
  • [Journal-full-title] Journal of plant physiology
  • [ISO-abbreviation] J. Plant Physiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Chlorides; 0 / Soil Pollutants; 3CYT62D3GA / aluminum chloride; RWP5GA015D / Potassium
  •  go-up   go-down


35. Greenwald J, Zeder-Lutz G, Hagege A, Celia H, Pattus F: The metal dependence of pyoverdine interactions with its outer membrane receptor FpvA. J Bacteriol; 2008 Oct;190(20):6548-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The accumulation of Pvd in the periplasm of Pseudomonas aeruginosa was also reduced in the treated growth medium, while the addition of 1 microM AlCl(3) to the treated medium restored the effects of trace metals observed in standard growth medium.
  • In light of our finding that the Pvd-Al complex is transported across the outer membrane of Pseudomonas aeruginosa, a model for siderophore recognition based on a metal-induced conformation followed by redox selectivity for iron is discussed.

  • MedlinePlus Health Information. consumer health - Iron.
  • Gene Ontology. gene/protein/disease-specific - Gene Ontology annotations from this paper .
  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • Hazardous Substances Data Bank. IRON, ELEMENTAL .
  • Hazardous Substances Data Bank. MANGANESE, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 2002 Feb 5;41(5):1663-71 [11814361.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):7072-7 [11997446.001]
  • [Cites] Biochemistry. 2002 Dec 10;41(49):14591-601 [12463759.001]
  • [Cites] J Mol Biol. 2003 Sep 12;332(2):353-68 [12948487.001]
  • [Cites] J Inorg Biochem. 2003 Dec 1;97(4):384-7 [14568244.001]
  • [Cites] Biochemistry. 2004 Jun 22;43(24):7954-65 [15196040.001]
  • [Cites] Biochemistry. 1971 Apr 13;10(8):1483-8 [5580666.001]
  • [Cites] Int J Pept Protein Res. 1972;4(3):157-66 [4342685.001]
  • [Cites] J Bacteriol. 1986 Jul;167(1):7-11 [3087966.001]
  • [Cites] Anal Biochem. 1991 Nov 1;198(2):268-77 [1724720.001]
  • [Cites] Appl Environ Microbiol. 1992 Sep;58(9):2886-93 [1444402.001]
  • [Cites] FEBS Lett. 1993 Jul 12;326(1-3):153-7 [8325363.001]
  • [Cites] J Bacteriol. 1993 Aug;175(15):4597-604 [8335619.001]
  • [Cites] Annu Rev Microbiol. 1994;48:743-72 [7826025.001]
  • [Cites] Anal Biochem. 1997 Nov 1;253(1):103-11 [9356148.001]
  • [Cites] Methods Mol Biol. 1998;103:107-20 [9680637.001]
  • [Cites] Biochemistry. 1999 Jul 20;38(29):9357-65 [10413510.001]
  • [Cites] J Mol Biol. 2005 Mar 18;347(1):121-34 [15733922.001]
  • [Cites] J Biol Chem. 2005 May 27;280(21):20222-30 [15784620.001]
  • [Cites] Chem Rev. 2005 Jun;105(6):1923-59 [15941206.001]
  • [Cites] Curr Opin Struct Biol. 2005 Aug;15(4):394-400 [16039843.001]
  • [Cites] J Mol Biol. 2005 Sep 30;352(4):893-904 [16139844.001]
  • [Cites] Biochemistry. 2005 Nov 1;44(43):14069-79 [16245923.001]
  • [Cites] Biopolymers. 2006;84(5):472-89 [16705688.001]
  • [Cites] J Biol Chem. 2007 Feb 2;282(5):2987-95 [17148441.001]
  • [Cites] J Clin Invest. 2007 Apr;117(4):877-88 [17364024.001]
  • [Cites] J Mol Recognit. 1999 Sep-Oct;12(5):279-84 [10556875.001]
  • [Cites] Annu Rev Microbiol. 2000;54:881-941 [11018148.001]
  • [Cites] Microbiology. 2000 Oct;146 ( Pt 10):2425-34 [11021919.001]
  • [Cites] Mol Microbiol. 2001 Jan;39(2):351-60 [11136456.001]
  • (PMID = 18641139.001).
  • [ISSN] 1098-5530
  • [Journal-full-title] Journal of bacteriology
  • [ISO-abbreviation] J. Bacteriol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Bacterial Outer Membrane Proteins; 0 / Culture Media; 0 / FpvA protein, Pseudomonas aeruginosa; 0 / Oligopeptides; 42Z2K6ZL8P / Manganese; 8062-00-8 / pyoverdin; CPD4NFA903 / Aluminum; E1UOL152H7 / Iron
  • [Other-IDs] NLM/ PMC2566188
  •  go-up   go-down


36. Miles RR, Cairo MS, Satwani P, Zwick DL, Lones MA, Sposto R, Abromovitch M, Tripp S, Angiolillo AL, Roman E, Davenport V, Perkins SL: Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report. Br J Haematol; 2007 Aug;138(4):506-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunophenotypic identification of possible therapeutic targets in paediatric non-Hodgkin lymphomas: a children's oncology group report.
  • Immunophenotypic analysis can identify protein epitopes in non-Hodgkin lymphomas (NHL) that may respond to targeted immunotherapies, such as anti-CD20 and anti-CD52.
  • Patient samples were derived from paediatric NHL clinical trials sponsored by the Children's Cancer Group (CCG, now the Children's Oncology Group, COG) and included Burkitt lymphoma (BL), diffuse large B-cell lymphoma (DLBCL), disseminated T- and B-cell lymphoblastic lymphoma (T-LBL and B-LBL) and anaplastic large cell (ALCL).
  • CD25 was expressed in 8% of T-LBL and 75% of ALCL cases, but not in BL, DLBCL, or B-LBL.
  • CD74 was expressed in 100% of B-LBL, BL and DLBCL, but was absent in ALCL and T-LBL.
  • CD80 was expressed in 12% of B-LBL, 6% of BL and 10% of DLBCL cases studied, but was not detected in T-cell NHL.
  • [MeSH-major] Antigens, CD / analysis. Lymphoma, Non-Hodgkin / immunology

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17659054.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD80; 0 / Antigens, Differentiation, B-Lymphocyte; 0 / Antigens, Neoplasm; 0 / CD52 antigen; 0 / Glycoproteins; 0 / Histocompatibility Antigens Class II; 0 / Interleukin-2 Receptor alpha Subunit; 0 / invariant chain
  •  go-up   go-down


37. Janková S, Císarová I, Uhlík F, Stepnicka P, Kotora M: Synthesis and characterisation of Dewar benzene-ferrocene conjugates. Dalton Trans; 2009 May 7;(17):3137-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first Dewar benzene-ferrocene conjugates were synthesised by the reaction of tetraalkylcyclobutadiene-AlCl(3) complexes with 3-ferrocenylpropynoates.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19421614.001).
  • [ISSN] 1477-9226
  • [Journal-full-title] Dalton transactions (Cambridge, England : 2003)
  • [ISO-abbreviation] Dalton Trans
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


38. Iyengar P, Reid-Nicholson M, Moreira AL: Pregnancy-associated anaplastic large-cell lymphoma of the breast: a rare mimic of ductal carcinoma. Diagn Cytopathol; 2006 Apr;34(4):298-302
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pregnancy-associated anaplastic large-cell lymphoma of the breast: a rare mimic of ductal carcinoma.
  • Anaplastic large-cell lymphoma (ALCL) is a rare T-cell lymphoma typically seen in children and young adults.
  • We herein report a case of ALCL arising in the breast of a 36-yr-old pregnant woman.
  • We would like to highlight the cytologic and histologic features of ALCL, as this case was initially misdiagnosed as a ductal carcinoma.
  • Differential diagnosis with other tumors is also discussed.
  • [MeSH-major] Breast / pathology. Carcinoma, Ductal, Breast / pathology. Lymphoma, Large-Cell, Anaplastic / pathology
  • [MeSH-minor] Adult. Biopsy, Fine-Needle. Diagnosis, Differential. Female. Humans. Pregnancy


39. Fringuelli F, Girotti R, Pizzo F, Vaccaro L: [AlCl3 + 2THF]: a new and efficient catalytic system for Diels-Alder cycloaddition of alpha,beta-unsaturated carbonyl compounds under solvent-free conditions. Org Lett; 2006 Jun 8;8(12):2487-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [AlCl(3) + 2THF] is a new catalytic system for the Diels-Alder cycloaddition under SFC and air atmosphere.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16737295.001).
  • [ISSN] 1523-7060
  • [Journal-full-title] Organic letters
  • [ISO-abbreviation] Org. Lett.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


40. Savage KJ: Prognosis and primary therapy in peripheral T-cell lymphomas. Hematology Am Soc Hematol Educ Program; 2008;:280-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognosis and primary therapy in peripheral T-cell lymphomas.
  • Peripheral NK/T-cell neoplasms are an uncommon group of diseases that show distinct racial and geographic variation.
  • The prognostic significance of the T-cell phenotype has been clearly defined in recent studies by using modern lymphoma classification systems.
  • However, within this heterogenous group of neoplasms, some have a more favorable prognosis, such as ALK-positive anaplastic large-cell leukemia (ALCL) and primary cutaneous ALCL, and some have ultimately fatal courses with standard chemotherapy programs (e.g., hepatosplenic gammadelta T-cell lymphomas).
  • Further, unlike the benefits observed with CHOP chemotherapy in the treatment of diffuse large B-cell lymphoma (DLBCL), peripheral T-cell lymphomas (PTCL), other than ALK-positive ALCL, are relatively chemoresistant to this regimen.
  • Given disease rarity and biological heterogeneity, advances in diagnosis, prognosis and treatment have lagged behind DLBCL.
  • Recently, however, studies are emerging that focus specifically on PTCLs with the ultimate goal of better understanding disease biology and developing more effective therapies.

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19074097.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; VB0R961HZT / Prednisone
  •  go-up   go-down


41. Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF, Tripp SR, Rassidakis GZ, Medeiros LJ, Szankasi P, Elenitoba-Johnson KS: The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood; 2009 Aug 20;114(8):1585-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Constitutive expression of the chimeric NPM/ALK fusion protein encoded by the t(2;5)(p32;q35) is a key oncogenic event in the pathogenesis of most anaplastic large cell lymphomas (ALCLs).
  • Using a mass spectrometry (MS)-driven approach to identify changes in protein expression caused by the NPM/ALK fusion, we identified diverse NPM/ALK-induced changes affecting cell proliferation, ribosome synthesis, survival, apoptosis evasion, angiogenesis, and cytoarchitectural organization.
  • MS-based findings were confirmed using Western blotting and/or immunostaining of NPM/ALK-transfected cells and ALK-deregulated lymphomas.
  • A subset of the proteins distinguished NPM/ALK-positive ALCLs from NPM/ALK-negative ALCLs and Hodgkin lymphoma.
  • In this regard, we showed loss of cell adhesion as a consequence of NPM/ALK expression in a kinase-dependent manner, and sensitivity of NPM/ALK-positive ALCLs to inhibition of the RAS, p42/44ERK, and FRAP/mTOR signaling pathways.
  • These findings reveal that the NPM/ALK alteration affects diverse cellular pathways, and provide novel insights into NPM/ALK-positive ALCL pathobiology.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / metabolism. Metabolic Networks and Pathways. Protein-Tyrosine Kinases / metabolism. Proteome / analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19531656.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Proteome; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases
  •  go-up   go-down


42. Chen CH, Chen SW, Shen WL, Chen TY, Tsao CJ, Huang WT: Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Int J Hematol; 2007 Feb;85(2):105-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful allogeneic stem cell transplantation for an adult with refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
  • Anaplastic lymphoma kinase (ALK) expression exists in approximately 60% of anaplastic large cell lymphoma (ALCL) cases.
  • Compared with the ALK-negative cases, ALK-positive cases are usually characterized by a good response to chemotherapy and a good prognosis.
  • In the relapsed or refractory ALCL cases, high-dose chemotherapy followed by autologous stem cell transplantation has been widely used as a salvage therapy.
  • However, 40% of patients who received transplants after more than 2 complete remissions eventually experienced disease progression, despite receiving autologous stem cell transplantation.
  • Allogeneic stem cell transplantation has been proposed as a therapeutic option in refractory ALCL cases, but clinical reports of adult patients are rare.
  • Herein, we report the case of an adult with refractory ALK-positive ALCL who was successfully treated with salvage high-dose chemotherapy followed by allogeneic stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma, Large-Cell, Anaplastic / therapy. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] Haematologica. 2005 Mar;90(3):ECR19 [15753060.001]
  • [Cites] Lancet Oncol. 2004 Feb;5(2):127-8 [14761818.001]
  • [Cites] Leukemia. 2005 Sep;19(9):1643-7 [16049513.001]
  • [Cites] Bone Marrow Transplant. 1999 Mar;23(5):437-42 [10100556.001]
  • [Cites] Blood. 1995 Sep 1;86(5):1954-60 [7655022.001]
  • [Cites] Blood. 1996 Feb 15;87(4):1243-8 [8608211.001]
  • [Cites] J Formos Med Assoc. 1998 Feb;97(2):123-6 [9509848.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):657-60 [2156024.001]
  • [Cites] Br J Haematol. 2001 Sep;114(4):741-60 [11564061.001]
  • [Cites] Eur J Haematol. 2005 Jul;75(1):22-6 [15946306.001]
  • [Cites] Br J Haematol. 2000 Jun;109(4):736-42 [10929023.001]
  • [Cites] Am J Clin Pathol. 1995 Jan;103(1):82-9 [7817951.001]
  • [Cites] Leuk Lymphoma. 1999 Sep;35(1-2):159-69 [10512173.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] Leuk Lymphoma. 1996 Sep;23(1-2):25-32 [9021682.001]
  • [Cites] Blood. 1985 Oct;66(4):848-58 [3876124.001]
  • (PMID = 17321986.001).
  • [ISSN] 0925-5710
  • [Journal-full-title] International journal of hematology
  • [ISO-abbreviation] Int. J. Hematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1; CVAD protocol
  •  go-up   go-down


43. Rekhi B, Sridhar E, Viswanathan S, Shet TM, Jambhekar NA: ALK+ anaplastic large cell lymphoma with cohesive, perivascular arrangements on cytology, mimicking a soft tissue sarcoma: a report of 2 cases. Acta Cytol; 2010 Jan-Feb;54(1):75-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK+ anaplastic large cell lymphoma with cohesive, perivascular arrangements on cytology, mimicking a soft tissue sarcoma: a report of 2 cases.
  • BACKGROUND: An accurate recognition of a lymphoma at an extranodal site is essential to avoid unnecessary excisions.
  • Fine needle aspiration cytology (FNAC) has been recognized as a useful tool in the primary diagnosis of soft tissue tumors.
  • An anaplastic large cell lymphoma (ALCL), occurring in soft tissues, poses a diagnostic challenge.
  • We present the cytomorphology of 2 cases of anaplastic lymphoma kinase (ALK)+ ALCL that displayed a perivascular arrangement, thereby mimicking a sarcoma.
  • Differential diagnoses included a rhabdomyosarcoma and a lymphoma.
  • On biopsy and immunohistochemistry, tumor cells were positive for vimentin, LCA, EMA, CD30 and ALK.
  • CONCLUSION: ALCL should be considered in the differential diagnosis of pediatric soft tissue tumors, especially in cases with multifocal involvement.
  • [MeSH-major] Biopsy, Fine-Needle. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoma, Large-Cell, Anaplastic / pathology. Protein-Tyrosine Kinases / metabolism. Soft Tissue Neoplasms / pathology
  • [MeSH-minor] Adolescent. Child. Diagnosis, Differential. Female. Humans. Immunohistochemistry. Male. Receptor Protein-Tyrosine Kinases. Sarcoma / pathology


44. Kovrigina AM, Probatova NA: [Diagnosis of anaplastic large-cell lymphoma]. Arkh Patol; 2005 Nov-Dec;67(6):7-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of anaplastic large-cell lymphoma].
  • Principles of morphological diagnosis of anaplastic large-cell lymphoma (ALCL) are considered, several its variants are distinguished: classic (32 cases), small-cell (4 cases), rich in granulocytes (2 cases) and lymphohistiocytic (1 case).
  • Morphological similarities between ALCL, classic variants of Hodgkin's lymphoma, variants of diffuse large B-cell lymphoma may require immunohistochemical investigation the criteria of which are suggested.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers, Tumor / metabolism. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Diagnosis, Differential. Female. Humans. Infant. Male. Middle Aged

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16405012.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


45. Newlove T, Loyd A, Patel R, Jelinek J, Latkowski JA: Primary cutaneous anaplastic large-cell lymphoma. Dermatol Online J; 2010;16(11):2
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous anaplastic large-cell lymphoma.
  • Primary cutaneous anaplastic large-cell lymphoma (ALCL) is a form of cutaneous T-cell lymphoma that is characterized by solitary or localized nodules or plaques.
  • Histopathologic features include a diffuse, non-epidermotropic infiltrate with cohesive sheets of large anaplastic CD30+ tumor cells.
  • This entity must be distinguished from systemic ALCL with cutaneous involvement and lymphomatoid papulosis.
  • Treatment modalities include clinical monitoring, radiation therapy, and surgical excision, with systemic chemotherapy reserved for disseminated or extracutaneous disease.
  • [MeSH-major] Lymphoma, Primary Cutaneous Anaplastic Large Cell / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Aged, 80 and over. Antigens, CD30 / metabolism. Combined Modality Therapy. Humans. Male. Treatment Outcome


46. Boccalatte FE, Voena C, Riganti C, Bosia A, D'Amico L, Riera L, Cheng M, Ruggeri B, Jensen ON, Goss VL, Lee K, Nardone J, Rush J, Polakiewicz RD, Comb MJ, Chiarle R, Inghirami G: The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL. Blood; 2009 Mar 19;113(12):2776-90
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The enzymatic activity of 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase/IMP cyclohydrolase is enhanced by NPM-ALK: new insights in ALK-mediated pathogenesis and the treatment of ALCL.
  • Anaplastic large cell lymphoma represents a subset of neoplasms caused by translocations that juxtapose the anaplastic lymphoma kinase (ALK) to dimerization partners.
  • To elucidate the ALK pathways sustaining lymphomagenesis and tumor maintenance, we analyzed the tyrosine-kinase protein profiles of ALK-positive cell lines using 2 complementary proteomic-based approaches, taking advantage of a specific ALK RNA interference (RNAi) or cell-permeable inhibitors.
  • ATIC phosphorylation was documented in cell lines and primary tumors carrying ALK proteins and other tyrosine kinases, including TPR-Met and wild type c-Met.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Biochemistry. 1999 Nov 16;38(46):15388-97 [10563825.001]
  • [Cites] Leuk Res. 2006 Sep;30(9):1097-104 [16464493.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):793-8 [10706082.001]
  • [Cites] Am J Pathol. 2000 Mar;156(3):781-9 [10702393.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2144-9 [10706887.001]
  • [Cites] Life Sci. 2000;66(23):2297-307 [10855951.001]
  • [Cites] Acta Crystallogr D Biol Crystallogr. 2000 Aug;56(Pt 8):1051-4 [10944351.001]
  • [Cites] J Biol Chem. 2001 Mar 16;276(11):7727-33 [11096114.001]
  • [Cites] Oncogene. 2002 Feb 7;21(7):1038-47 [11850821.001]
  • [Cites] Clin Chem. 2002 Jun;48(6 Pt 1):835-43 [12028998.001]
  • [Cites] Mol Cell Proteomics. 2002 May;1(5):376-86 [12118079.001]
  • [Cites] Oncogene. 2002 Aug 29;21(38):5823-34 [12185581.001]
  • [Cites] J Proteome Res. 2003 Mar-Apr;2(2):137-46 [12716127.001]
  • [Cites] Oncogene. 2004 Apr 8;23(15):2617-29 [14968112.001]
  • [Cites] Proc Natl Acad Sci U S A. 1985 Aug;82(15):4881-5 [3860829.001]
  • [Cites] Blood. 1989 May 1;73(6):1468-75 [2469492.001]
  • [Cites] J Mol Biol. 1992 Sep 5;227(1):283-92 [1522592.001]
  • [Cites] J Biol Chem. 1996 Jan 26;271(4):2225-33 [8567683.001]
  • [Cites] Adv Exp Med Biol. 1998;431:221-6 [9598063.001]
  • [Cites] J Biol Chem. 1957 Sep;228(1):201-13 [13475309.001]
  • [Cites] Anal Biochem. 1963 Jul;6:100-8 [13995604.001]
  • [Cites] J Biol Chem. 2004 Nov 12;279(46):47726-31 [15358777.001]
  • [Cites] Nat Biotechnol. 2005 Jan;23(1):94-101 [15592455.001]
  • [Cites] Mol Cell Proteomics. 2005 Mar;4(3):310-27 [15665377.001]
  • [Cites] Mol Cell Proteomics. 2006 Oct;5(10):1787-98 [16785248.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3171-82 [17111047.001]
  • [Cites] Blood. 2006 Dec 15;108(13):4202-4 [16946300.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5 [17185414.001]
  • [Cites] Blood. 2007 Mar 1;109(5):2156-64 [17077326.001]
  • [Cites] Cell Signal. 2007 Apr;19(4):740-7 [17110082.001]
  • [Cites] Mol Cancer. 2007;6:25 [17407558.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4278-86 [17483340.001]
  • [Cites] Exp Hematol. 2007 Aug;35(8):1240-8 [17560012.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Jan 15;105(2):692-7 [18180459.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3907-16 [16105984.001]
  • [Cites] Biochem J. 2006 Jan 15;393(Pt 2):555-64 [16197368.001]
  • [Cites] Blood. 2006 Jan 15;107(2):689-97 [16189272.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1617-23 [16254137.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 May 9;103(19):7402-7 [16651537.001]
  • [Cites] Proteomics. 2006 May;6(10):3210-22 [16596703.001]
  • [Cites] Blood. 2006 Jun 15;107(12):4888-97 [16497976.001]
  • [CommentIn] Blood. 2009 Mar 19;113(12):2615-6 [19299651.001]
  • (PMID = 18845790.001).
  • [ISSN] 1528-0020
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA090773; United States / NCI NIH HHS / CA / R01-CA90773
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / CEP 11988; 0 / CEP 14083; 0 / Carbazoles; 0 / Cell Adhesion Molecules; 0 / Indazoles; 0 / Microfilament Proteins; 0 / Multienzyme Complexes; 0 / Neoplasm Proteins; 0 / Phenylurea Compounds; 0 / Phosphoproteins; 0 / Protein Kinase Inhibitors; 0 / inosine monophosphate synthase; 0 / vasodilator-stimulated phosphoprotein; 21820-51-9 / Phosphotyrosine; EC 2.1.2.- / Hydroxymethyl and Formyl Transferases; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 3.5.4.- / Nucleotide Deaminases; YL5FZ2Y5U1 / Methotrexate
  • [Other-IDs] NLM/ PMC2661863
  •  go-up   go-down


47. Horie R: [Molecular basis of Hodgkin lymphoma and anaplastic large cell lymphoma and molecular targeting therapy by an NF-kappaB inhibitor]. Rinsho Ketsueki; 2007 Apr;48(4):255-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Molecular basis of Hodgkin lymphoma and anaplastic large cell lymphoma and molecular targeting therapy by an NF-kappaB inhibitor].
  • [MeSH-major] Gene Targeting. Genetic Therapy. Hodgkin Disease / genetics. Hodgkin Disease / therapy. Lymphoma, Large B-Cell, Diffuse / genetics. Lymphoma, Large B-Cell, Diffuse / therapy. NF-kappa B / antagonists & inhibitors
  • [MeSH-minor] Antigens, CD30. Humans. Protein-Tyrosine Kinases


48. Turner SD, Alexander DR: What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis? Leukemia; 2005 Jul;19(7):1128-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) is generated as a t(2;5) chromosomal breakpoint product, typically in CD30(+) anaplastic large cell lymphomas.
  • [MeSH-major] Lymphoma / immunology. Oncogene Proteins, Fusion / immunology. Protein-Tyrosine Kinases / immunology
  • [MeSH-minor] Animals. Disease Models, Animal. Humans. Mice. Mice, Transgenic. Phosphorylation. Signal Transduction / genetics. Signal Transduction / immunology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902287.001).
  • [ISSN] 0887-6924
  • [Journal-full-title] Leukemia
  • [ISO-abbreviation] Leukemia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; EC 2.7.1.- / p80(NPM-ALK) protein; EC 2.7.10.1 / Protein-Tyrosine Kinases
  • [Number-of-references] 65
  •  go-up   go-down


49. Liffourrena AS, Salvano MA, Lucchesi GI: Pseudomonas putida A ATCC 12633 oxidizes trimethylamine aerobically via two different pathways. Arch Microbiol; 2010 Jun;192(6):471-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In both conditions, the trimethylamine was used as a nitrogen source and also accumulated in the cell, slowing the bacterial growth.
  • Decreased bacterial growth was counteracted by the addition of AlCl(3).
  • Cell-free extracts prepared from cells grown aerobically on tetradecyltrimethylammonium bromide exhibited trimethylamine monooxygenase activity that produced trimethylamine N-oxide and trimethylamine N-oxide demethylase activity that produced dimethylamine.
  • Cell-free extracts from cells grown on trimethylamine exhibited trimethylamine dehydrogenase activity that produced dimethylamine, which was oxidized to methanal and methylamine by dimethylamine dehydrogenase.

  • Hazardous Substances Data Bank. DIMETHYLAMINE .
  • Hazardous Substances Data Bank. TRIMETHYLAMMONIUM CHLORIDE .
  • Hazardous Substances Data Bank. METHYLAMINE .
  • Hazardous Substances Data Bank. TRIMETHYLAMINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20437165.001).
  • [ISSN] 1432-072X
  • [Journal-full-title] Archives of microbiology
  • [ISO-abbreviation] Arch. Microbiol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Dimethylamines; 0 / Methylamines; 0 / Trimethyl Ammonium Compounds; ARQ8157E0Q / dimethylamine; BSF23SJ79E / methylamine; EC 1.13.- / Oxygenases; EC 1.14.99.- / tertiary amine monooxygenase; EC 1.5.- / Oxidoreductases, N-Demethylating; EC 1.5.8.2 / trimethylamine dehydrogenase; FLD0K1SJ1A / trimethyloxamine; LHH7G8O305 / trimethylamine; Y3IR7RCT6J / tetradecyltrimethylammonium
  •  go-up   go-down


50. Balwierz W, Czogała M, Czepko E: [Anaplastic large cell lymphoma associated with hemophagocytic lymphohistiocytosis: a case report and review of the literature]. Przegl Lek; 2010;67(6):436-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Anaplastic large cell lymphoma associated with hemophagocytic lymphohistiocytosis: a case report and review of the literature].
  • Here we present a case report of a 14 years old boy diagnosed with HLH before recognition of anaplastic large cell lymphoma (ALCL).
  • Finally, histopathological examination of a subsequently excised enlarged lymph node demonstrated lesions typical for ALCL.
  • First-line therapy, according to protocol for this type of lymphoma, was introduced.
  • He was qualified for allogeneic stem cell transplantation.
  • Occurrence of HLH can cause diagnostic difficulties, because it often masks the underlying disease, especially when it is associated with infection.
  • [MeSH-major] Lymphohistiocytosis, Hemophagocytic / diagnosis. Lymphohistiocytosis, Hemophagocytic / etiology. Lymphoma, Large-Cell, Anaplastic / complications. Lymphoma, Large-Cell, Anaplastic / diagnosis
  • [MeSH-minor] Adolescent. Adult. Child. Disease Progression. Fatal Outcome. Humans. Lymph Nodes / pathology. Male. Remission Induction. Stem Cell Transplantation


51. McCune RC, Syrbu SI, Vasef MA: Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol; 2006 Jul;19(7):1010-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays.
  • Analysis of B-cell-specific transcription factors is useful in understanding of the differentiation-linked phenotype in Hodgkin's as well as in non-Hodgkin's lymphomas.
  • We analyzed the expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in 109 cases, including non-Hodgkin's lymphomas of B- and T-lineage, classical Hodgkin's lymphomas, and nodular lymphocyte predominant Hodgkin's lymphomas.
  • Our study revealed that all transcription factors were universally expressed in all cases of nodular lymphocyte predominant Hodgkin's and variably expressed in non-Hodgkin's lymphomas of B-lineage.
  • Cases of classical Hodgkin's lymphoma variably expressed the Pax-5, Oct-1, Oct-2, and BOB.1.
  • However, in contrast to nodular lymphocyte predominant Hodgkin's lymphoma, the transcription factor PU.1 was consistently absent in all cases of classical Hodgkin's lymphoma.
  • Transcription factors Pax-5, BOB.1, and PU.1 were not detectable in cases of anaplastic large cell lymphoma.
  • However, the Oct-1 was detected in all anaplastic large cells lymphoma cases, indicating that expression of this transcription factor was not restricted to B-lineage lymphoid malignancies.
  • Our findings suggest that inclusion of the PU.1 antibody may prove useful in separating classical Hodgkin's lymphomas from nodular lymphocyte predominant Hodgkin's lymphomas in problematic cases.
  • [MeSH-major] B-Cell-Specific Activator Protein / metabolism. Hodgkin Disease / metabolism. Lymphoma, Non-Hodgkin / metabolism. Proto-Oncogene Proteins / metabolism. Tissue Array Analysis. Trans-Activators / metabolism
  • [MeSH-minor] Diagnosis, Differential. Humans. Immunohistochemistry. Octamer Transcription Factor-1 / metabolism. Octamer Transcription Factor-2 / metabolism. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16648862.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / Octamer Transcription Factor-1; 0 / Octamer Transcription Factor-2; 0 / PAX5 protein, human; 0 / POU2AF1 protein, human; 0 / Proto-Oncogene Proteins; 0 / Trans-Activators; 0 / proto-oncogene protein Spi-1
  •  go-up   go-down


52. Horny HP, Sotlar K, Valent P: Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review. Pathobiology; 2010;77(4):169-80
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential diagnoses of systemic mastocytosis in routinely processed bone marrow biopsy specimens: a review.
  • Diagnosis of systemic mastocytosis (SM) is mainly based on the morphological demonstration of compact mast cell infiltrates in various tissue sites.
  • Reliable immunohistochemical markers for the diagnosis and grading of SM have been established, but various differential diagnoses including myeloproliferative neoplasms, basophilic and eosinophilic leukemias may be very difficult to delineate.
  • Even more challenging is the recognition of hematological neoplasms with signs of mast cell differentiation but not fulfilling diagnostic criteria for SM, especially the rare myelomastocytic leukemia.
  • It is also important to separate the reactive state of mast cell hyperplasia from indolent variants of SM, especially those with a very low degree of bone marrow infiltration and absence of compact mast cell infiltrates.
  • When the lymphocytic component of the SM infiltrate is very prominent, SM may be confused with an indolent lymphoma, especially lymphoplasmacytic lymphoma which almost always shows a marked reactive increase in mast cells.
  • Regarding immunohistochemical anomalies, mast cells in aggressive and leukemic SM have been found to express CD30 (Ki1-antigen).
  • Thus, anaplastic large cell lymphoma or Hodgkin's disease may first be considered rather than SM.
  • There is increasing evidence that most patients with long-standing adult-type urticaria pigmentosa-like skin lesions have in fact indolent SM.
  • Therefore, such skin lesions are an important clue to the correct diagnosis in these patients.
  • However, in aggressive or leukemic SM skin lesions are usually absent and then the correct diagnosis relies on an appropriate investigation of bone marrow biopsy specimens using both SM-related immunohistochemical markers (tryptase, KIT, CD25, CD30) but also markers excluding potential differential diagnoses.
  • Investigation for presence of the activating KIT point mutation D816V is very helpful to establish a correct diagnosis of SM in all the difficult cases exhibiting a low degree of bone marrow infiltration or puzzling morphological findings.
  • [MeSH-major] Bone Marrow / pathology. Mastocytosis, Systemic / diagnosis
  • [MeSH-minor] Adult. Basophils / immunology. Basophils / pathology. Biopsy. Diagnosis, Differential. Humans. Mast Cells / immunology. Mast Cells / pathology. Myeloproliferative Disorders / diagnosis. Myeloproliferative Disorders / genetics. Myeloproliferative Disorders / immunology. Point Mutation. Urticaria Pigmentosa / diagnosis. Urticaria Pigmentosa / genetics. Urticaria Pigmentosa / pathology

  • Genetic Alliance. consumer health - Mast cell disease.
  • Genetic Alliance. consumer health - Systemic mastocytosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20616612.001).
  • [ISSN] 1423-0291
  • [Journal-full-title] Pathobiology : journal of immunopathology, molecular and cellular biology
  • [ISO-abbreviation] Pathobiology
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  •  go-up   go-down


53. Maugel N, Mann FM, Hillwig ML, Peters RJ, Snider BB: Synthesis of (+/-)-nosyberkol (isotuberculosinol, revised structure of edaxadiene) and (+/-)-tuberculosinol. Org Lett; 2010 Jun 4;12(11):2626-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Me(2)AlCl-catalyzed Diels-Alder reaction of N-tigloyloxazolidinone with 6,6-dimethyl-1-vinylcyclohexene selectively provided the exo adduct, which was converted to nosyberkol (isotuberculosinol) and tuberculosinol.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Chem Soc. 2002 Nov 6;124(44):13171-8 [12405845.001]
  • [Cites] J Org Chem. 2003 Sep 19;68(19):7400-6 [12968892.001]
  • [Cites] J Am Chem Soc. 2003 Oct 1;125(39):11796-7 [14505383.001]
  • [Cites] J Am Chem Soc. 2009 Dec 9;131(48):17526-7 [19583202.001]
  • [Cites] J Nat Prod. 2004 Nov;67(11):1932-5 [15568794.001]
  • [Cites] Chem Commun (Camb). 2005 Feb 28;(8):1016-8 [15719101.001]
  • [Cites] J Biol Chem. 2009 Aug 28;284(35):23574-9 [19574210.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Sep 14;101(37):13642-7 [15340136.001]
  • (PMID = 20462237.001).
  • [ISSN] 1523-7052
  • [Journal-full-title] Organic letters
  • [ISO-abbreviation] Org. Lett.
  • [Language] ENG
  • [Grant] United States / NIGMS NIH HHS / GM / R01 GM050151-16; United States / NIGMS NIH HHS / GM / GM050151; United States / NIGMS NIH HHS / GM / R01 GM076324; United States / NIGMS NIH HHS / GM / GM076324; United States / NIGMS NIH HHS / GM / R01 GM076324-05; United States / NIGMS NIH HHS / GM / R01 GM050151
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diterpenes; 0 / edaxadiene; 0 / tuberculosinol
  • [Other-IDs] NLM/ NIHMS204856; NLM/ PMC2880386
  •  go-up   go-down


54. Yamagiwa N, Suto Y, Torisawa Y: Convenient method for the addition of disulfides to alkenes. Bioorg Med Chem Lett; 2007 Nov 15;17(22):6197-201
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While reactions by FeCl(3) were feasible with cycloalkenes and other simple alkenes, much faster and excellent conversions were possible by AlCl(3) even with the substrates less reactive toward FeCl(3).

  • Hazardous Substances Data Bank. FERRIC CHLORIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17888660.001).
  • [ISSN] 0960-894X
  • [Journal-full-title] Bioorganic & medicinal chemistry letters
  • [ISO-abbreviation] Bioorg. Med. Chem. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Alkenes; 0 / Chlorides; 0 / Cycloparaffins; 0 / Disulfides; 0 / Ferric Compounds; U38V3ZVV3V / ferric chloride
  •  go-up   go-down


55. Rianthavorn P, Cain JP, Turman MA: Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH. Pediatr Nephrol; 2008 Aug;23(8):1367-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of conivaptan to allow aggressive hydration to prevent tumor lysis syndrome in a pediatric patient with large-cell lymphoma and SIADH.
  • We report a case of a 13-year-old boy with extensively metastasized anaplastic large-cell lymphoma.
  • Conivaptan played a significant role in this situation by allowing provision of a large amount of intravenous fluid prior to and during induction chemotherapy.
  • [MeSH-major] Benzazepines / administration & dosage. Hyponatremia / drug therapy. Inappropriate ADH Syndrome / drug therapy. Lymphoma, Large B-Cell, Diffuse / complications. Tumor Lysis Syndrome / prevention & control

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Drug Rev. 2007 Fall;25(3):261-79 [17919259.001]
  • [Cites] Int J Biochem Cell Biol. 2003 Nov;35(11):1495-9 [12824060.001]
  • [Cites] Best Pract Res Clin Endocrinol Metab. 2003 Dec;17(4):471-503 [14687585.001]
  • [Cites] Postgrad Med J. 2006 Mar;82(965):216-9 [16517805.001]
  • [Cites] Ann Intern Med. 1985 Feb;102(2):164-8 [3966753.001]
  • [Cites] Am J Health Syst Pharm. 2007 Jul 1;64(13):1385-95 [17592003.001]
  • [Cites] J Intensive Care Med. 2003 Jan-Feb;18(1):3-8 [15189662.001]
  • [Cites] Am J Nephrol. 2007;27(5):447-57 [17664863.001]
  • [Cites] Am J Nephrol. 2005 May-Jun;25(3):240-9 [15914973.001]
  • (PMID = 18437428.001).
  • [ISSN] 0931-041X
  • [Journal-full-title] Pediatric nephrology (Berlin, Germany)
  • [ISO-abbreviation] Pediatr. Nephrol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Benzazepines; 0NJ98Y462X / conivaptan
  •  go-up   go-down


56. Johnston M, Lee JJ, Chottiner GS, Miller B, Tsuda T, Hussey CL, Scherson DA: Electrochemistry in ultrahigh vacuum: underpotential deposition of Al on polycrystalline W and Au from room temperature AlCl(3)/1-ethyl-3-methylimidazolium chloride melts. J Phys Chem B; 2005 Jun 9;109(22):11296-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Electrochemistry in ultrahigh vacuum: underpotential deposition of Al on polycrystalline W and Au from room temperature AlCl(3)/1-ethyl-3-methylimidazolium chloride melts.
  • The voltammetric characteristics of polycrystalline Au and W electrodes cleaned (thermal annealing at 1100 K) and characterized (Auger electron spectroscopy) in ultrahigh vacuum (UHV) have been examined in ultrapure AlCl(3)/1-ethyl-3-methylimidazolium chloride (EtMeImCl) melts in UHV.
  • These experiments were performed using a custom-designed transfer system that allows for the all-Al electrochemical cell to be filled with EtMeImCl in an auxiliary UHV chamber and later transferred under UHV to the main UHV chamber that houses the Auger electron spectrometer.
  • This behavior is unlike that reported in the literature for experiments performed in a glovebox, which required either extensive potential cycling in the Al bulk deposition and stripping region or excursions to potentials positive enough for chlorine evolution to ensue for Al UPD features to be clearly discerned.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16852379.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


57. Tamiolakis D, Papadopoulos N, Venizelos J, Kakagia D, Nikolaidou S, Bolioti S, Kouskoukis C: ALK-positive neutrophil-rich variant of anaplastic large cell lymphoma diagnosed after head trauma. Onkologie; 2005 Jun;28(6-7):356-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive neutrophil-rich variant of anaplastic large cell lymphoma diagnosed after head trauma.
  • BACKGROUND: Anaplastic lymphoma kinase (ALK) expression has not been described in neutrophil-rich anaplastic large cell lymphoma (NR-ALCL).
  • CASE REPORT: A 12-year old female with a 4-weeks history of a non-resolving bump over the forehead resulting from injury, was diagnosed of stage IE cutaneous T-cell lymphoma, and radiation was employed.
  • Shortly after completion of therapy, there was progress of the disease on the soft tissue of the right hand, and bone marrow involvement was also found.
  • A fine-needle aspiration of the hand mass was performed, and a diagnosis of CD30+/ALK+ NR-ALCL, was rendered.
  • METHODS: We studied the morphological characteristics of CD30+/ALK+ NR-ALCL using histological methods.
  • A panel of antibodies were used to establish diagnosis and subtyping.
  • CONCLUSIONS: ALK-ALCL arising in the skin represents a single disease with a broad spectrum of morphology; clinicians and pathologists should be aware of this neutrophil-rich (NR) variant with aggressive clinical presentation.
  • [MeSH-major] Lymphoma, Large B-Cell, Diffuse / blood. Lymphoma, Large B-Cell, Diffuse / pathology. Neutrophils / pathology. Protein-Tyrosine Kinases / blood. Skin Neoplasms / blood. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933425.001).
  • [ISSN] 0378-584X
  • [Journal-full-title] Onkologie
  • [ISO-abbreviation] Onkologie
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


58. Ji TH, Li HL, Jiang HY, Zhao T, Yu YH: [Expression of ALK protein in large cell lymphoma with ALCL chromosome translocation in relation to prognosis]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Jun;16(3):543-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of ALK protein in large cell lymphoma with ALCL chromosome translocation in relation to prognosis].
  • The aim of this study was to investigate the expression of anaplastic lymphoma kinase (ALK) protein resulted from chromosome translocation in anaplastic large cell lymphoma (ALCL) and its relationship with the age and prognosis of patients with ALCL.
  • The tissue microarray including 30 cases of ALCL and 2 normal control tissues were established, the expression of anaplastic lymphoma kinase (ALK) protein was detected by immunohistochemistry, the statistical analysis of detected results was carried out by SPSS software.
  • The results showed that the ALK protein was expressed negatively in 2 cases of primary skin ALCL, but in 20 out of 28 cases of systematic ALCL the ALK protein was expressed positively and mainly located in cytoplasm and/or nucleus (71.4%).
  • It is concluded that there is a high incidence of ALK expression in ALCL, especially in younger group.
  • ALK expression may be an useful and independent marker for the differential diagnosis and prognosis evaluation of ALCL.

  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18549625.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


59. Mann G, Attarbaschi A, Burkhardt B, Niggli F, Klapper W, Ludwig WD, Schrappe M, Zimmermann M, Gadner H, Reiter A, Berlin-Frankfurt-Münster Group: Clinical characteristics and treatment outcome of infants with non-Hodgkin lymphoma. Br J Haematol; 2007 Nov;139(3):443-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and treatment outcome of infants with non-Hodgkin lymphoma.
  • Non-Hodgkin lymphoma (NHL) is rarely observed during infancy and data on its incidence, characteristics and outcome are scarce.
  • We identified 20 (1%) infants with NHL including five with T-cell lymphoblastic lymphoma (T-cell LBL), seven with precursor B-cell LBL (pB-cell LBL), two with a mature Burkitt neoplasm, five with anaplastic large cell lymphoma (ALCL) and one with peripheral T-cell lymphoma (PTCL).
  • The PTCL patient, 3/7 pB-cell LBL and 1/5 ALCL patients relapsed.
  • One patient each from the T-cell LBL and Burkitt lymphoma groups suffered from a second malignancy and one patient each with ALCL and Burkitt leukaemia died from treatment-related toxicity.
  • This study has provided preliminary evidence that infants with NHL have a dismal prognosis and showed that infant NHL differed to lymphomas in older patients with respect to the distribution of gender, histopathologic subtypes as well as the ratio of T- to pB-cell LBL and the frequency of relapses of pB-cell LBL.
  • [MeSH-major] Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Europe / epidemiology. Female. Humans. Infant. Lymphoma, B-Cell / epidemiology. Lymphoma, B-Cell / therapy. Lymphoma, Large-Cell, Anaplastic / epidemiology. Lymphoma, Large-Cell, Anaplastic / therapy. Lymphoma, T-Cell / epidemiology. Lymphoma, T-Cell / therapy. Male. Neoplasm Staging. Precursor Cell Lymphoblastic Leukemia-Lymphoma / epidemiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Prognosis. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868047.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


60. Alvarez P, Blanco C, Granda M: The adsorption of chromium (VI) from industrial wastewater by acid and base-activated lignocellulosic residues. J Hazard Mater; 2007 Jun 1;144(1-2):400-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The activated carbons were prepared from a lignocellulosic raw material by thermal treatment at 450 and 650 degrees C in the presence of acid (AlCl(3), HCl, H(3)PO(4) and H(2)SO(4)) and base (NaOH) agents.

  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. SODIUM HYDROXIDE .
  • Hazardous Substances Data Bank. CARBON .
  • Hazardous Substances Data Bank. CHROMIUM, ELEMENTAL .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • Hazardous Substances Data Bank. HYDROGEN CHLORIDE .
  • Hazardous Substances Data Bank. PHOSPHORIC ACID .
  • Hazardous Substances Data Bank. Sulfuric acid .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17126488.001).
  • [ISSN] 0304-3894
  • [Journal-full-title] Journal of hazardous materials
  • [ISO-abbreviation] J. Hazard. Mater.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Chlorides; 0 / Industrial Waste; 0 / Phosphoric Acids; 0 / Sulfuric Acids; 0 / Water Pollutants, Chemical; 0R0008Q3JB / Chromium; 11132-73-3 / lignocellulose; 18540-29-9 / chromium hexavalent ion; 3CYT62D3GA / aluminum chloride; 55X04QC32I / Sodium Hydroxide; 7440-44-0 / Carbon; 9004-34-6 / Cellulose; 9005-53-2 / Lignin; E4GA8884NN / phosphoric acid; O40UQP6WCF / sulfuric acid; QTT17582CB / Hydrochloric Acid
  •  go-up   go-down


61. Chen RF, Chen CT, Liao HT, Chen CH, Chen YR: Primary cutaneous anaplastic large cell lymphoma of the face presenting as posttraumatic maxillary sinusitis. J Craniofac Surg; 2008 Nov;19(6):1597-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous anaplastic large cell lymphoma of the face presenting as posttraumatic maxillary sinusitis.
  • Primary cutaneous anaplastic large cell lymphoma (ALCL) is an uncommon disease.
  • It has various presentations that may mislead the diagnosis and cause delay of treatment.
  • The patient was first treated for maxillary sinusitis according to clinical history, but the pathology turned out to be primary cutaneous ALCL.
  • The presentations of primary cutaneous ALCL of the face may mimic posttraumatic maxillary sinusitis.
  • [MeSH-major] Cheek / pathology. Facial Neoplasms / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Skin Neoplasms / diagnosis
  • [MeSH-minor] Child. Diagnosis, Differential. Facial Injuries / diagnosis. Follow-Up Studies. Humans. Male. Maxillary Fractures / diagnosis. Maxillary Sinusitis / diagnosis. Soft Tissue Infections / diagnosis. Wounds, Nonpenetrating / diagnosis. Zygomatic Fractures / diagnosis


62. El-Sayed AM, El-Borai MH, Bahnassy AA, El-Gerzawi SM: Flow cytometric immunophenotyping (FCI) of lymphoma: correlation with histopathology and immunohistochemistry. Diagn Pathol; 2008;3:43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Flow cytometric immunophenotyping (FCI) of lymphoma: correlation with histopathology and immunohistochemistry.
  • BACKGROUND: To evaluate the role of flow cytometric immunophenotyping (FCI) in diagnosis and characterization of lymphoma tissue specimens from Egyptian patients.
  • METHODS: FCI using 2 and 3 color staining approaches, was performed on 50 fresh lymph nodes specimen from Cairo NCI patients with suspected lymphoma presenting with either localized or generalized lymphadenopathy.FCI results were correlated with histopathologic as well as immunophenotypic[by immunohistochemistry (IHC)] findings.
  • RESULTS: By FCI, cases were diagnosed as follows: 9(18%) reactive hyperplasia (RH), 32(64%) B-cell non-Hodgkin's lymphoma (B-NHL) [24 diffuse large (DLBCL), 2 follicular, 3 small lymphocytic, 2 mantle cell lymphoma and a case of T cell rich B cell lymphoma], 3 (6%) T cell NHL [2 peripheral T cell lymphoma and a case of anaplastic large cell lymphoma], 2(4%) Hodgkin's lymphoma (HL) while 4 (8%) were non-lymphomatous tumors (NLT).
  • The sensitivity and specificity of FCI in diagnosis of NHL was 94.9% and 100% respectively; in HL they were 40% and 100% respectively and in NLT, both sensitivity and specificity were 100% while for RH were 100% and 89.1% respectively.
  • CONCLUSION: FCI is a sensitive and specific method in diagnosis and classification of NHL as well as in detection of monoclonality.
  • False negative results could be due to the presence of heterogeneous populations of lymphocytes in special types of lymphoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Pathol. 2008;3:25 [18534037.001]
  • [Cites] Diagn Pathol. 2006;1:36 [17034635.001]
  • [Cites] Diagn Cytopathol. 2006 May;34(5):335-47 [16604559.001]
  • [Cites] Recenti Prog Med. 2005 Jun;96(6):284-90 [16078757.001]
  • [Cites] Methods Mol Med. 2005;115:65-91 [15998963.001]
  • [Cites] Cytometry B Clin Cytom. 2005 Mar;64(1):34-42 [15669024.001]
  • [Cites] Praxis (Bern 1994). 2004 Oct 6;93(41):1687-92 [15535602.001]
  • [Cites] J Korean Med Sci. 1999 Aug;14(4):393-400 [10485618.001]
  • [Cites] Blood. 1999 May 15;93(10):3487-93 [10233901.001]
  • [Cites] Cancer. 1998 Aug 25;84(4):252-61 [9723601.001]
  • [Cites] J Clin Pathol. 1998 Mar;51(3):189-96 [9659258.001]
  • [Cites] Diagn Cytopathol. 1997 Mar;16(3):200-6 [9099538.001]
  • [Cites] Cytometry. 1996 Oct 1;25(2):113-24 [8891441.001]
  • [Cites] Clin Diagn Lab Immunol. 1994 May;1(3):299-303 [7496966.001]
  • [Cites] Ann Clin Lab Sci. 1994 Jan-Feb;24(1):6-11 [8147568.001]
  • [Cites] Cytometry. 1991;12(4):350-9 [1712263.001]
  • [Cites] Am J Clin Pathol. 1990 Sep;94(3):280-6 [2204263.001]
  • [Cites] Arch Pathol Lab Med. 2004 Sep;128(9):1004-22 [15335254.001]
  • [Cites] Cancer. 2004 Feb 25;102(1):55-65 [14968418.001]
  • [Cites] Cas Lek Cesk. 2003;142(11):651-5 [14689823.001]
  • [Cites] Haematologica. 2003 Dec;88(12):1358-65 [14687988.001]
  • [Cites] J Invest Dermatol. 2003 Dec;121(6):1522-30 [14675205.001]
  • [Cites] Cytometry B Clin Cytom. 2003 Nov;56(1):8-15 [14582132.001]
  • [Cites] BMJ. 2003 Sep 27;327(7417):716-9 [14512479.001]
  • [Cites] Cytopathology. 2001 Jun;12(3):168-76 [11380558.001]
  • [Cites] Mod Pathol. 2001 May;14(5):472-81 [11353059.001]
  • [Cites] Cytometry. 2001 Feb 15;46(1):23-7 [11241503.001]
  • [Cites] Cytometry. 2000 Oct 15;42(5):296-306 [11025488.001]
  • [Cites] East Mediterr Health J. 1999 Sep;5(5):1035-41 [10983545.001]
  • [Cites] Hum Pathol. 2000 Apr;31(4):422-7 [10821487.001]
  • (PMID = 18986555.001).
  • [ISSN] 1746-1596
  • [Journal-full-title] Diagnostic pathology
  • [ISO-abbreviation] Diagn Pathol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2637251
  •  go-up   go-down


63. Rodig SJ, Ouyang J, Juszczynski P, Currie T, Law K, Neuberg DS, Rabinovich GA, Shipp MA, Kutok JL: AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features. Clin Cancer Res; 2008 Jun 1;14(11):3338-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] AP1-dependent galectin-1 expression delineates classical hodgkin and anaplastic large cell lymphomas from other lymphoid malignancies with shared molecular features.
  • We recently found that Reed-Sternberg cell Gal1 promotes the immunosuppressive T-helper 2/T-regulatory cell-skewed microenvironment in classical Hodgkin lymphoma (cHL).
  • In addition, because there are common signaling and survival pathways in cHL and additional non-Hodgkin lymphomas, we also evaluated whether the AP1/Gal1 signature is shared by other molecularly or morphologically related lymphomas.
  • EXPERIMENTAL DESIGN: We evaluated 225 cases of primary cHL and non-Hodgkin lymphoma for evidence of a functional AP1/Gal1 signature by immunohistochemical techniques.
  • In contrast, diffuse large B-cell lymphoma, primary mediastinal large B-cell lymphoma, and another Hodgkin-related entity, nodular lymphocyte-predominant Hodgkin lymphoma, do not express Gal1.
  • However, anaplastic large cell lymphoma (ALCL), consistently expresses both Gal1 and its transcriptional regulator, c-Jun.
  • The presence of activated c-Jun, indicative of functional AP1 activity, was confirmed by phospho-c-Jun immunostaining in cHL and ALCL.
  • CONCLUSIONS: These findings establish a functional AP1 signature that includes Gal1 expression in cHL and ALCL and suggests a common mechanism for tumor immunotolerance in these diseases.
  • In addition, the combination of Gal1 and c-Jun serve as diagnostic biomarkers that delineate cHL and ALCL from other lymphomas with shared morphologic and/or molecular features.
  • [MeSH-major] Biomarkers, Tumor / analysis. Galectin 1 / biosynthesis. Hodgkin Disease / metabolism. Lymphoma, Large-Cell, Anaplastic / metabolism. Lymphoproliferative Disorders / metabolism. Transcription Factor AP-1 / metabolism
  • [MeSH-minor] Diagnosis, Differential. Gene Expression. Humans. Immunohistochemistry. Proto-Oncogene Proteins c-jun / metabolism. Reed-Sternberg Cells / metabolism


64. Anastasov N, Bonzheim I, Rudelius M, Klier M, Dau T, Angermeier D, Duyster J, Pittaluga S, Fend F, Raffeld M, Quintanilla-Martinez L: C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway. Haematologica; 2010 May;95(5):760-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] C/EBPβ expression in ALK-positive anaplastic large cell lymphomas is required for cell proliferation and is induced by the STAT3 signaling pathway.
  • BACKGROUND: Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma is characterized by the t(2;5) chromosomal translocation, resulting in the expression of a fusion protein formed of nucleophosmin (NPM) and ALK.
  • Recently, we reported the abnormal expression of the transcription factor CCAAT/enhancer binding protein-beta (C/EBPbeta) in ALK-positive anaplastic large cell lymphomas, and demonstrated its dependence on NPM-ALK activity.
  • DESIGN AND METHODS: In this study, the role of C/EBPbeta in proliferation and survival of ALK-positive anaplastic large cell lymphomas was investigated, as well as the mechanism of its expression and activity.
  • RESULTS: Interference with C/EBPbeta expression resulted in a dramatic decrease in cell proliferation in ALK-positive anaplastic large cell lymphomas, with a mild induction of apoptosis after 6 days.
  • Down-regulation of STAT3 resulted in a marked decrease in C/EBPbeta mRNA and protein levels with impairment in cell proliferation and viability, underscoring the important role of these two proteins in ALK-mediated oncogenesis.
  • [MeSH-major] CCAAT-Enhancer-Binding Protein-beta / biosynthesis. Cell Proliferation. Gene Expression Regulation, Neoplastic. Lymphoma, Large-Cell, Anaplastic / enzymology. Receptor Protein-Tyrosine Kinases / biosynthesis. STAT3 Transcription Factor / physiology. Signal Transduction
  • [MeSH-minor] Animals. Cell Line. Cell Line, Transformed. Cell Line, Tumor. Cell Survival / genetics. Down-Regulation / genetics. Humans. Mice


65. Murthy JK, Gross U, Rüdiger S, Rao VV, Kumar VV, Wander A, Bailey CL, Harrison NM, Kemnitz E: Aluminum chloride as a solid is not a strong Lewis acid. J Phys Chem B; 2006 Apr 27;110(16):8314-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The (001) surface of crystalline AlCl(3) is the natural cleavage plane and its structure is predicted via first principles calculations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16623514.001).
  • [ISSN] 1520-6106
  • [Journal-full-title] The journal of physical chemistry. B
  • [ISO-abbreviation] J Phys Chem B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


66. Gómez-Román JJ, Cobo ML, Val-Bernal JF: Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm. Pathol Int; 2008 Apr;58(4):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma presenting as a bladder neoplasm.
  • Malignant lymphoma presenting in the bladder has been classified in primary cases, as the first sign of disseminated disease and as a secondary infiltration.
  • Reported herein is the case of a 45-year-old man with an anaplastic large cell lymphoma (anaplastic lymphoma kinase (ALK) and granzyme B positive) that presented as a bladder neoplasm.
  • The morphological differential diagnosis was complex because the EMA-positive immunophenotype, CD45 and CD3 negativity and the clinical manifestation simulated a transitional cell carcinoma.
  • It is important to be aware of its existence because a poorly differentiated bladder carcinoma cannot be ruled out if CD30 and ALK immunostaining are not performed.
  • T-cell receptor-gamma clonal rearrangement could be also helpful in these cases.
  • Although bladder involvement by recurrent lymphoma is a sign of widely disseminated disease and it is associated with a very poor prognosis, it seems that chemotherapeutic regimens in this kind of ALK-positive lymphoma could be effective, given that the present patient had an impressive response to chemotherapy treatment.
  • [MeSH-major] Carcinoma, Transitional Cell / diagnosis. Lymphoma, Large-Cell, Anaplastic / diagnosis. Protein-Tyrosine Kinases / metabolism. Urinary Bladder Neoplasms / diagnosis
  • [MeSH-minor] Antigens, CD30 / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism. Cisplatin / administration & dosage. Cytarabine / administration & dosage. Diagnosis, Differential. Disease-Free Survival. Etoposide / administration & dosage. Humans. Male. Methylprednisolone / administration & dosage. Middle Aged. Mucin-1 / metabolism. Receptor Protein-Tyrosine Kinases. Treatment Outcome


67. Georgakis GV, Li Y, Rassidakis GZ, Medeiros LJ, Younes A: The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression. Exp Hematol; 2006 Dec;34(12):1670-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
  • OBJECTIVE: Heat shock protein 90 (HSP90) chaperones and maintains the molecular integrity of a variety of signal transduction proteins, including the nucleophosmin-anaplastic lymphoma kinase (NPM-ALK) oncogenic protein, a genetic abnormality that is frequently observed in anaplastic large cell lymphoma (ALCL) cells.
  • Here we demonstrate that HSP90 is overexpressed in primary and cultured ALK-positive and ALK-negative ALCL cells, and we evaluate the potential role of the small molecule inhibitor of HSP90, 17-allylamino-17-demethoxygeldanamycin (17-AAG) in treating ALCL.
  • Apoptosis and cell-cycle arrest were determined by Annexin-V/propidium iodide and propidium iodide staining, respectively, and fluorescein-activated cell sorting analysis.
  • RESULTS: Treatment of cultured ALCL cells with 17-AAG induced cell-cycle arrest and apoptosis, irrespective of ALK expression.
  • At the molecular level, 17-AAG induced degradation of ALK and Akt proteins, dephosphorylated extracellular signal-regulated kinase, and degraded the cell-cycle regulatory protein cyclin D1 and its cyclin-dependent kinases, CDK4 and CDK6, but had a differential effect on p27 and p53 proteins.
  • Inhibition of extracellular signal-regulated kinase phosphorylation by the mitogen activated protein kinase inhibitor U0126 induced cell death in all ALCL cell lines, and sublethal concentration 17-AAG showed synergistic antiproliferative effects when combined with U0126 or doxorubicin.
  • CONCLUSION: Our data demonstrate that targeting HSP90 function by 17-AAG may offer a novel therapeutic strategy for ALCL, either as single-agent activity or by combining 17-AAG with conventional or targeted therapeutic schemes.
  • [MeSH-major] Benzoquinones / pharmacology. Butadienes / pharmacology. Doxorubicin / pharmacology. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / pharmacology. Lymphoma, Large-Cell, Anaplastic / metabolism. Nitriles / pharmacology. Protein-Tyrosine Kinases / biosynthesis
  • [MeSH-minor] Apoptosis / drug effects. Caspase 3 / drug effects. Caspase 3 / metabolism. Cell Line, Tumor. Cell Proliferation / drug effects. Cyclin D. Cyclin-Dependent Kinase 4 / drug effects. Cyclin-Dependent Kinase 4 / metabolism. Cyclin-Dependent Kinase 6 / drug effects. Cyclin-Dependent Kinase 6 / metabolism. Cyclins / drug effects. Cyclins / metabolism. Dose-Response Relationship, Drug. Down-Regulation / drug effects. Drug Synergism. Extracellular Signal-Regulated MAP Kinases / drug effects. Extracellular Signal-Regulated MAP Kinases / metabolism. G0 Phase / drug effects. G1 Phase / drug effects. Humans. Mitogen-Activated Protein Kinase 1 / drug effects. Mitogen-Activated Protein Kinase 1 / metabolism. Mitogen-Activated Protein Kinase 3 / drug effects. Mitogen-Activated Protein Kinase 3 / metabolism. Phosphorylation. Receptor Protein-Tyrosine Kinases. Time Factors

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17157164.001).
  • [ISSN] 0301-472X
  • [Journal-full-title] Experimental hematology
  • [ISO-abbreviation] Exp. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Benzoquinones; 0 / Butadienes; 0 / Cyclin D; 0 / Cyclins; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 0 / Nitriles; 0 / U 0126; 4GY0AVT3L4 / tanespimycin; 80168379AG / Doxorubicin; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / CDK6 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 2.7.11.22 / Cyclin-Dependent Kinase 6; EC 2.7.11.24 / Extracellular Signal-Regulated MAP Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 1; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 3; EC 3.4.22.- / Caspase 3
  •  go-up   go-down


68. Tokura Y, Sugita K, Yagi H, Shimauchi T, Kabashima K, Takigawa M: Primary cutaneous anaplastic large cell lymphoma with fatal leukemic outcome in association with CLA and CCR4-negative conversion. J Am Acad Dermatol; 2007 Nov;57(5 Suppl):S92-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous anaplastic large cell lymphoma with fatal leukemic outcome in association with CLA and CCR4-negative conversion.
  • A 70-year-old Japanese male presented with a 1-year history of skin tumors, which were diagnosed as primary cutaneous anaplastic large cell lymphoma (ALCL) because of the CD3(low+), CD4(+), CD25(+), CD30(+), CD45RO(+), CD71(+), HLA-DR(+), CD8(-), CD56(-), and NPM/ALK(-) phenotype and monoclonal T-cell receptor-rearranged property of tumor cells as well as the absence of systemic involvement.
  • At this time, the tumor cell was positive for cutaneous lymphocyte-associated antigen (CLA) and TH(2) chemokine receptor CCR4.
  • The eruption had repeatedly appeared and spontaneously regressed or regressed by virtue of several therapeutic modalities, including radiotherapy, interferon-alpha and chemotherapy, until the tumor cell invaded the gastric mucosa and spread to the peripheral blood 5 years later.
  • Flow cytometric monitoring of the phenotype of peripheral blood and skin-infiltrating lymphocytes disclosed that the expression of CLA and CCR4 on the tumor cells was converted from positive to negative in association with the leukemic change.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Leukemia / etiology. Lymphoma, Large B-Cell, Diffuse / complications. Lymphoma, Large B-Cell, Diffuse / metabolism. Membrane Glycoproteins / metabolism. Receptors, Chemokine / metabolism

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17938033.001).
  • [ISSN] 1097-6787
  • [Journal-full-title] Journal of the American Academy of Dermatology
  • [ISO-abbreviation] J. Am. Acad. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation, T-Lymphocyte; 0 / Antigens, Neoplasm; 0 / CCR4 protein, human; 0 / CTAGE1 protein, human; 0 / Membrane Glycoproteins; 0 / Receptors, CCR4; 0 / Receptors, Chemokine
  •  go-up   go-down


69. Piccaluga PP, Agostinelli C, Califano A, Carbone A, Fantoni L, Ferrari S, Gazzola A, Gloghini A, Righi S, Rossi M, Tagliafico E, Zinzani PL, Zupo S, Baccarani M, Pileri SA: Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation. Cancer Res; 2007 Nov 15;67(22):10703-10
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression analysis of angioimmunoblastic lymphoma indicates derivation from T follicular helper cells and vascular endothelial growth factor deregulation.
  • Angioimmunoblastic lymphoma (AILT) is the second most common subtype of peripheral T-cell lymphoma (PTCL) and is characterized by dismal prognosis.
  • We performed gene expression profile (GEP) analysis of six AILT, six anaplastic large cell lymphomas (ALCL), 28 PTCL-unspecified (PTCL/U), and 20 samples of normal T lymphocytes (including CD4(+), CD8(+), and activated and resting subpopulations), aiming to (a) assess the relationship of AILT with other PTCLs, (b) establish the relationship between AILT and normal T-cell subsets, and (c) recognize the cellular programs deregulated in AILT possibly looking for novel potential therapeutic targets.
  • [MeSH-major] Gene Expression Profiling. Gene Expression Regulation, Neoplastic. Lymphoma / genetics. Lymphoma / metabolism. Lymphoma, T-Cell, Peripheral / metabolism. NF-kappa B / metabolism. Proto-Oncogene Proteins c-rel / biosynthesis. T-Lymphocytes, Helper-Inducer / metabolism. Vascular Endothelial Growth Factor A / biosynthesis
  • [MeSH-minor] CD4-Positive T-Lymphocytes / metabolism. CD8-Positive T-Lymphocytes / metabolism. Humans. Immune System. Immunohistochemistry / methods. Oligonucleotide Array Sequence Analysis. T-Lymphocytes / metabolism

  • Genetic Alliance. consumer health - Follicular Lymphoma.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18006812.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / NF-kappa B; 0 / Proto-Oncogene Proteins c-rel; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


70. Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, Ohtomo K, Kanda Y, Chiba S, Motokura T, Kurokawa M: FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol; 2007 Oct;18(10):1685-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDG-PET in T-cell and NK-cell neoplasms.
  • BACKGROUND: A growing number of studies demonstrate the utility of (18)fluoro-2-deoxyglucose positron emission tomography (FDG-PET) in the management of malignant lymphoma.
  • The results of FDG-PET, however, have not been studied extensively for T-cell and natural killer (NK)-cell neoplasms.
  • PATIENTS AND METHODS: We retrospectively evaluated pretreatment FDG-PET scans in 41 patients with T/NK-cell neoplasms diagnosed according to the World Health Organization (WHO) classification.
  • Histological subtypes frequently included were peripheral T-cell lymphoma, unspecified (PTCLu, n = 11), extranodal NK/T-cell lymphoma, nasal type (ENKL, n = 8), primary cutaneous anaplastic large cell lymphoma (C-ALCL, n = 5), and angioimmunoblastic T-cell lymphoma (AILT, n = 4).
  • RESULTS: FDG-PET detected a lymphoma lesion in at least one site in 36 out of 41 patients.
  • The positive rate was equally high in most histological subtypes except for cutaneous lymphomas: PTCLu 91%, ENKL 100%, C-ALCL 60%, AILT 100%.
  • The positive rate of FDG-PET for bone marrow involvement was only 20%.
  • CONCLUSION: T/NK-cell neoplasms incorporated in this study were generally FDG-avid except for cutaneous lesions and bone marrow involvement.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17716987.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


71. Casulo C, Horwitz S: Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting? Curr Oncol Rep; 2010 Nov;12(6):374-82
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Should eligible patients with T-cell lymphoma receive high-dose therapy and autologous stem cell transplant in the upfront setting?
  • Peripheral T-cell lymphomas (PTCL) are rare and aggressive subtypes of non-Hodgkin's lymphoma.
  • Compared to B cell lymphomas, the immunologic phenotype of PTCL portends a poorer prognosis, with the exception of anaplastic large cell lymphoma bearing the anaplastic lymphoma kinase protein.
  • Patients with PTCL tend to present clinically in advanced disease states, show lower response rates to chemotherapy, and suffer from more frequent relapses and shorter remissions.
  • The rarity of these lymphomas has made it difficult to carry out prospective, randomized trials delineating optimal treatments.
  • Consequently, high-dose chemotherapy and autologous stem cell transplantation (ASCT) have been actively studied in both the relapsed and upfront setting.
  • In addition, the impact of disease status at transplantation is being investigated, though the optimal disease state at transplant is still a matter of debate, as is the timing of transplant.
  • This article seeks to review the literature on the role of ASCT in PTCL, as well as to clarify what may be the optimal disease state in which to offer patients with PTCL autologous transplantation, if at all.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral
  • [MeSH-minor] Combined Modality Therapy. Disease Progression. Disease-Free Survival. Humans. Lymphoma, B-Cell / therapy. Randomized Controlled Trials as Topic. Risk Factors. Secondary Prevention. Survival Rate. Transplantation Conditioning. Transplantation, Autologous. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2002 Jan;13(1):140-9 [11863096.001]
  • [Cites] J Clin Oncol. 2001 Sep 1;19(17):3766-70 [11533100.001]
  • [Cites] Br J Haematol. 2003 Mar;120(6):978-85 [12648067.001]
  • [Cites] Ann Oncol. 2003 Dec;14(12):1768-75 [14630683.001]
  • [Cites] Bone Marrow Transplant. 2004 Feb;33(4):405-10 [14676776.001]
  • [Cites] Blood. 2004 Apr 1;103(7):2474-9 [14645001.001]
  • [Cites] Cancer. 1984 Aug 15;54(4):687-96 [6234983.001]
  • [Cites] J Clin Oncol. 1989 Dec;7(12):1783-90 [2585020.001]
  • [Cites] Ann Oncol. 1990;1(1):45-50 [1706610.001]
  • [Cites] N Engl J Med. 1993 Sep 30;329(14):987-94 [8141877.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2296-301 [9196143.001]
  • [Cites] Blood. 1998 Jul 1;92(1):76-82 [9639502.001]
  • [Cites] Cancer. 2005 May 15;103(10):2091-8 [15816054.001]
  • [Cites] Cancer. 2005 Dec 1;104(11):2437-41 [16216001.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 Jul;58(1):35-9 [16308699.001]
  • [Cites] Br J Haematol. 2006 Jul;134(2):202-7 [16759221.001]
  • [Cites] Leukemia. 2006 Sep;20(9):1533-8 [16871285.001]
  • [Cites] Haematologica. 2007 Feb;92(2):271-2 [17296587.001]
  • [Cites] Ann Oncol. 2007 Apr;18(4):652-7 [17229774.001]
  • [Cites] Eur J Haematol. 2007 Jul;79(1):32-8 [17598836.001]
  • [Cites] Bone Marrow Transplant. 2007 Aug;40(3):239-43 [17530000.001]
  • [Cites] Bone Marrow Transplant. 2007 Sep;40(5):443-50 [17589529.001]
  • [Cites] Ann Oncol. 2008 May;19(5):958-63 [18303032.001]
  • [Cites] J Clin Oncol. 2008 Sep 1;26(25):4124-30 [18626005.001]
  • [Cites] J Clin Oncol. 2009 Jan 1;27(1):106-13 [19029417.001]
  • [Cites] Biol Blood Marrow Transplant. 2009 Jan;15(1):118-25 [19135950.001]
  • [Cites] Blood. 2010 Feb 4;115(5):1026-36 [19965671.001]
  • [Cites] Ann Oncol. 2010 Apr;21(4):860-3 [19887465.001]
  • [Cites] J Clin Oncol. 2000 Aug;18(16):3025-30 [10944137.001]
  • [Cites] Bone Marrow Transplant. 2001 Apr;27(7):711-6 [11360110.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10):2472-9 [12011124.001]
  • (PMID = 20737300.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA009207
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS577493; NLM/ PMC4075438
  •  go-up   go-down


72. Chan JK, Kwong YL: Common misdiagnoses in lymphomas and avoidance strategies. Lancet Oncol; 2010 Jun;11(6):579-88
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Common misdiagnoses in lymphomas and avoidance strategies.
  • Lymphoma diagnosis integrates clinical, morphological, immunophenotypical, and molecular genetic features, as shown in WHO classifications of lymphoid malignancies.
  • Diagnosis of lymphoma is challenging.
  • Reactive lesions such as Kikuchi lymphadenitis, infectious mononucleosis, autoimmune lymphoproliferative syndrome, and immunoglobulin G4-related sclerosing disease can be misdiagnosed as lymphomas.
  • Anaplastic large-cell lymphoma variants that are positive for anaplastic lymphoma kinase, classical Hodgkin's lymphoma variants, and infarcted lymphomas might be misdiagnosed as reactive disorders.
  • Difficulties with classification of lymphomas are also encountered, such as the distinction of classical Hodgkin's lymphoma from anaplastic large-cell lymphoma that is negative for anaplastic lymphoma kinase.
  • Interpretation of immunophenotyping results is complicated in some cases by aberrant or cross-lineage expression of lymphoid antigens on lymphomas, and the occasional lymphoid antigen expression on non-lymphoid malignancies.
  • [MeSH-major] Diagnostic Errors. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20227918.001).
  • [ISSN] 1474-5488
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD3
  • [Number-of-references] 74
  •  go-up   go-down


73. Lankoff A, Banasik A, Duma A, Ochniak E, Lisowska H, Kuszewski T, Góźdź S, Wojcik A: A comet assay study reveals that aluminium induces DNA damage and inhibits the repair of radiation-induced lesions in human peripheral blood lymphocytes. Toxicol Lett; 2006 Feb 8;161(1):27-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Cells were treated with different doses of aluminium chloride (1, 2, 5, 10 and 25 microg/ml AlCl(3)) for 72 h.
  • Based on the fluorescence intensity, cells were divided into cohorts of different relative DNA content that corresponds to G(1), S and G(2) phases of the cell cycle.
  • [MeSH-minor] Adult. Apoptosis / drug effects. Cell Cycle / drug effects. DNA / drug effects. DNA / genetics. DNA / radiation effects. Dose-Response Relationship, Drug. Flow Cytometry. Humans. Purines / chemistry. Purines / metabolism. Pyrimidines / chemistry. Pyrimidines / metabolism. Time Factors

  • Hazardous Substances Data Bank. ALUMINUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16139969.001).
  • [ISSN] 0378-4274
  • [Journal-full-title] Toxicology letters
  • [ISO-abbreviation] Toxicol. Lett.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Purines; 0 / Pyrimidines; 9007-49-2 / DNA; CPD4NFA903 / Aluminum
  •  go-up   go-down


74. Brites V, Hammoutène D, Hochlaf M: Spectroscopy, metastability, and single and double ionization of AlCl. J Phys Chem A; 2008 Dec 25;112(51):13419-26
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Spectroscopy, metastability, and single and double ionization of AlCl.
  • Large calculations are done to investigate the valence and inner-valence electronic states of aluminum monochloride and its cationic species AlCl+ and AlCl2+, allowing their definite assignment.
  • For the neutral molecule, our calculations show that the lifetimes of the AlCl A1pi v' > or = 10 levels are reduced to the 0.1-0.01 ps time scale because of spin-orbit induced predissociation processes and by tunneling through the potential barrier of the A state.
  • Our potential curves for the ground state of AlCl and those of the cationic and dicationic species are also used for predicting the single and double ionization spectrum of AlCl.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19053555.001).
  • [ISSN] 1520-5215
  • [Journal-full-title] The journal of physical chemistry. A
  • [ISO-abbreviation] J Phys Chem A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


75. Abramson SJ, Price AP: Imaging of pediatric lymphomas. Radiol Clin North Am; 2008 Mar;46(2):313-38, ix
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of pediatric lymphomas.
  • Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) represent 10% to 15% of all malignancies occurring in children younger than 20 years of age.
  • This article reviews the clinical features of lymphoma, focusing on the spectrum of imaging findings seen in diagnosis, staging, and follow-up of HL and NHL.
  • Pediatric NHL has four major histologic subtypes: Burkitt lymphoma, diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and lymphoblastic lymphoma.
  • [MeSH-major] Diagnostic Imaging. Lymphoma / diagnosis

  • MedlinePlus Health Information. consumer health - Diagnostic Imaging.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18619383.001).
  • [ISSN] 0033-8389
  • [Journal-full-title] Radiologic clinics of North America
  • [ISO-abbreviation] Radiol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 127
  •  go-up   go-down


76. Muto A, Nakagawa A, Shimomura Y, Kitagawa Y, Tsurusawa M: Antineoplastic agents for pediatric anaplastic large cell lymphoma: Vinblastine is the most effective in vitro. Leuk Lymphoma; 2005 Oct;46(10):1489-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antineoplastic agents for pediatric anaplastic large cell lymphoma: Vinblastine is the most effective in vitro.
  • Anti-neoplastic effects of a total of 11 agents (adriamycin, briplatin, cytarabine, dexamethasone, etoposide, 4-hydroperoxycyclophosphamide, 4-hydroperoxyifosphamide, methotrexate, predonisolone, vinblastine, vincristine) were tested on 4 cell lines (DEL, Ki-JK, SR-786, SU-DHL-1) established from pediatric ALCL cases.
  • The individual cell lines were treated with those agents at different concentrations (0.01 microM/L, 0.1 microM/L, 1 microM/L, 10 microM/L, 100 microM/L) for 1 h or 24 h, and their cellular growths were measured by the microculture tetrozolium (MTT) assay.
  • Of those anti-neoplastic agents, methotrexate, vinblastine, and vincristine were highly effective on the cell growth inhibition in all these cell lines with time- and dose-dependent manner.
  • Among them, vinblastine was found to be the most effective in 3 cell lines (DEL, Ki-JK, SR786) with 50% effective doses (ED50, concentrations causing 50% cell survival after treatment) ranging from 0.0016 to 1.27 microM/L for the 1-h treatment and 0.0002 - 0.59 microM/L for the 24-h treatment.
  • Further experiments demonstrated that vinblastine treatment induced cellular apoptosis and caused severe disruption in mitotic spindle formation on these cell lines.
  • The results support the protocol of ALCL 99 study, which uses vinblastine as one of the first-line anti-neoplastic agents for the high-risk ALCL patients in the pediatric age group.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Lymphoma, Large-Cell, Anaplastic / pathology. Vinblastine / pharmacology
  • [MeSH-minor] Cell Line, Tumor. Cell Survival / drug effects. Humans. Tubulin / metabolism


77. Lysell J, Wiegleb Edström D, Linde A, Carlsson G, Malmros-Svennilson J, Westermark A, Andersson J, Wahlgren CF: Antiviral therapy in children with hydroa vacciniforme. Acta Derm Venereol; 2009;89(4):393-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Association with Epstein-Barr virus infection and a possibly increased risk of lymphoproliferative malignancy have been demonstrated.
  • However, one patient progressed into an anaplastic lymphoma kinase-1-negative anaplastic large-cell lymphoma in the upper jaw.
  • [MeSH-minor] Child. Child, Preschool. DNA, Viral / analysis. Drug Therapy, Combination. Female. Herpesvirus 4, Human / genetics. Humans. Jaw Diseases / virology. Lymphoma, Large B-Cell, Diffuse / virology. Male. Oral Ulcer / virology

  • Genetic Alliance. consumer health - Hydroa vacciniforme.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Valacyclovir .
  • Hazardous Substances Data Bank. ACYCLOVIR .
  • Hazardous Substances Data Bank. L-Valine .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19688153.001).
  • [ISSN] 1651-2057
  • [Journal-full-title] Acta dermato-venereologica
  • [ISO-abbreviation] Acta Derm. Venereol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Sweden
  • [Chemical-registry-number] 0 / Antiviral Agents; 0 / DNA, Viral; HG18B9YRS7 / Valine; MZ1IW7Q79D / valacyclovir; X4HES1O11F / Acyclovir
  •  go-up   go-down


78. Uner AH, Sağlam A, Han U, Hayran M, Sungur A, Ruacan S: PTEN and p27 expression in mature T-cell and NK-cell neoplasms. Leuk Lymphoma; 2005 Oct;46(10):1463-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PTEN and p27 expression in mature T-cell and NK-cell neoplasms.
  • Loss of Pten and p27 expressions were examined immunohistochemically in 45 patients with peripheral T- and NK-cell lymphoma.
  • Partial or complete loss of Pten was detected in 66.7% of the cases of anaplastic large cell lymphoma (ALCL) compared to only 12.5% of all other mature T-/NK-cell lymphomas combined.
  • Loss of p27 was identified in 64.9% of cases, which showed a positive correlation with Pten loss.
  • In this study, we showed that loss of Pten is more frequent in ALCL as compared to other mature T-/NK-cell lymphomas, which strongly correlates with the loss of p27 expression.
  • Our findings provide further evidence for the importance of the deregulation of the PI3K-AKT pathway in ALCL.
  • [MeSH-major] Cyclin-Dependent Kinase Inhibitor p27 / metabolism. Gene Expression Regulation, Neoplastic. Killer Cells, Natural / pathology. Lymphoma / metabolism. Lymphoma / pathology. PTEN Phosphohydrolase / metabolism. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16194892.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 147604-94-2 / Cyclin-Dependent Kinase Inhibitor p27; EC 3.1.3.48 / PTEN protein, human; EC 3.1.3.67 / PTEN Phosphohydrolase
  •  go-up   go-down


79. Erdogan-Orhan I, Sever-Yılmaz B, Altun ML, Saltan G: Radical quenching activity, ferric-reducing antioxidant power, and ferrous ion-chelating capacity of 16 Ballota species and their total phenol and flavonoid contents. J Med Food; 2010 Dec;13(6):1537-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Total phenol and flavonoid contents of the extracts were determined by Folin-Ciocalteau and AlCl(3) reagents, respectively.
  • The extracts showed insignificant quenching activity against DPPH radical, but they had moderate antioxidant activity (0.597 ± 0.03 to 1.342 ± 0.01) in the ferric-reducing test compared to chlorogenic acid (the reference compound) (3.618 ± 0.01).

  • MedlinePlus Health Information. consumer health - Antioxidants.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21091260.001).
  • [ISSN] 1557-7600
  • [Journal-full-title] Journal of medicinal food
  • [ISO-abbreviation] J Med Food
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antioxidants; 0 / Diterpenes; 0 / Flavonoids; 0 / Food Preservatives; 0 / Free Radical Scavengers; 0 / Iron Chelating Agents; 0 / Phenols; 0 / Plant Extracts; 0 / Solvents; 0 / hispanolone
  •  go-up   go-down


80. Tripathi S, Mahdi AA, Nawab A, Chander R, Hasan M, Siddiqui MS, Mahdi F, Mitra K, Bajpai VK: Influence of age on aluminum induced lipid peroxidation and neurolipofuscin in frontal cortex of rat brain: a behavioral, biochemical and ultrastructural study. Brain Res; 2009 Feb 9;1253:107-16
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The markers of oxidative stress, e.g. lipid peroxides and endogenous antioxidants as well as metals (Al, Fe, Cu, Zn and Se) were measured in the brain frontal cortex of young and aged rats fed with AlCl(3) (100 mg/kg b.w.) for 90 days and normal saline treated controls.
  • On the basis of the results of the present study, we conclude that Al may be linked with neurolipofuscinogenesis and alteration in neurobehavioral activity and these changes may be responsible for the development of age related disorders, such as Alzheimer's disease.

  • MedlinePlus Health Information. consumer health - Seniors' Health.
  • Hazardous Substances Data Bank. ALUMINUM COMPOUNDS .
  • Hazardous Substances Data Bank. ALUMINUM CHLORIDE .
  • Hazardous Substances Data Bank. SELENIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19073157.001).
  • [ISSN] 1872-6240
  • [Journal-full-title] Brain research
  • [ISO-abbreviation] Brain Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Aluminum Compounds; 0 / Antioxidants; 0 / Chlorides; 0 / Lipid Peroxides; 0 / Lipofuscin; 0 / Metals, Heavy; 3CYT62D3GA / aluminum chloride; H6241UJ22B / Selenium
  •  go-up   go-down


81. Calzado-Villarreal L, Polo-Rodríguez I, Ortiz-Romero PL: [Primary cutaneous CD30+ lymphoproliferative disorders]. Actas Dermosifiliogr; 2010 Mar;101(2):119-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary cutaneous CD30+ lymphoproliferative disorders].
  • [Transliterated title] Síndrome linfoproliferativo CD30+ cutáneo primario.
  • CD30+ lymphoproliferative disorders are the most common group of cutaneous T-cell lymphomas after mycosis fungoides and its subtypes.
  • This group includes lymphomatoid papulosis and CD30+ anaplastic large-cell lymphoma; these 2 entities are the extremes of a spectrum with numerous intermediate varieties in which it is not possible to establish a clear diagnosis based on clinical and histopathologic criteria.
  • CD30+ lymphoproliferative disorders must be differentiated from other lymphoproliferative diseases with CD30+ cells in the tumor infiltrates, such as mycosis fungoides or Hodgkin disease, and also from other inflammatory conditions or nonhematological neoplasms that can include this cell type, such as pityriasis lichenoides et varioliformis acuta or certain mesenchymal tumors (CD30+ pseudolymphomas).
  • In contrast to their systemic homologues, which arise in the lymph nodes, CD30+ lymphoproliferative disorders generally have a good prognosis.
  • It is very important to exclude the presence of a lymphoma of systemic origin with extralymphatic spread, as the prognosis and treatment are different.
  • [MeSH-major] Antigens, CD30 / analysis. Lymphoproliferative Disorders / pathology. Skin Diseases / pathology
  • [MeSH-minor] Aged. Antigens, Neoplasm / analysis. Biomarkers, Tumor. Clone Cells / chemistry. Clone Cells / pathology. Diagnosis, Differential. Humans. Lymphoma, Primary Cutaneous Anaplastic Large Cell / chemistry. Lymphoma, Primary Cutaneous Anaplastic Large Cell / pathology. Lymphomatoid Papulosis / metabolism. Lymphomatoid Papulosis / pathology. Middle Aged. Pseudolymphoma / metabolism. Pseudolymphoma / pathology. Skin Neoplasms / metabolism. Skin Neoplasms / pathology. T-Lymphocytes / chemistry. T-Lymphocytes / pathology

  • MedlinePlus Health Information. consumer health - Skin Conditions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20223154.001).
  • [ISSN] 1578-2190
  • [Journal-full-title] Actas dermo-sifiliográficas
  • [ISO-abbreviation] Actas Dermosifiliogr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor
  • [Number-of-references] 29
  •  go-up   go-down


82. Webb TR, Slavish J, George RE, Look AT, Xue L, Jiang Q, Cui X, Rentrop WB, Morris SW: Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy. Expert Rev Anticancer Ther; 2009 Mar;9(3):331-56
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapy.
  • Anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase in the insulin receptor superfamily, was initially identified in constitutively activated oncogenic fusion forms - the most common being nucleophosmin-ALK - in anaplastic large-cell lymphomas, and subsequent studies have identified ALK fusions in diffuse large B-cell lymphomas, systemic histiocytosis, inflammatory myofibroblastic tumors, esophageal squamous cell carcinomas and non-small-cell lung carcinomas.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Crit Rev Oncol Hematol. 2006 Dec;60(3):216-26 [16860997.001]
  • [Cites] Biochem Biophys Res Commun. 2006 Dec 29;351(4):839-46 [17094947.001]
  • [Cites] Am J Surg Pathol. 2006 Dec;30(12):1502-12 [17122505.001]
  • [Cites] World J Gastroenterol. 2006 Nov 28;12(44):7104-12 [17131471.001]
  • [Cites] J Clin Invest. 2006 Dec;116(12):3171-82 [17111047.001]
  • [Cites] Ann Oncol. 2000 Jan;11(1):53-8 [10690387.001]
  • [Cites] Cancer Res. 2000 Feb 15;60(4):793-8 [10706082.001]
  • [Cites] Blood. 2000 Mar 15;95(6):2144-9 [10706887.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2603-8 [10706604.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Apr 21;270(3):936-41 [10772929.001]
  • [Cites] Am J Pathol. 2000 May;156(5):1711-21 [10793082.001]
  • [Cites] Br J Haematol. 2000 Jun;109(3):584-91 [10886208.001]
  • [Cites] Am J Pathol. 2000 Aug;157(2):377-84 [10934142.001]
  • [Cites] Science. 2000 Sep 15;289(5486):1938-42 [10988075.001]
  • [Cites] Curr Oncol Rep. 2002 Jul;4(4):317-24 [12044241.001]
  • [Cites] Br J Haematol. 2002 Jun;117(4):812-20 [12060115.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Aug;34(4):354-62 [12112524.001]
  • [Cites] Int J Cancer. 2002 Jul 1;100(1):49-56 [12115586.001]
  • [Cites] Genes Chromosomes Cancer. 2001 May;31(1):85-90 [11284039.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):419-26 [11310834.001]
  • [Cites] Blood. 1999 Nov 15;94(10):3509-15 [10552961.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1483-90 [9057627.001]
  • [Cites] Mol Cell Biol. 1997 Apr;17(4):2312-25 [9121481.001]
  • [Cites] J Biol Chem. 1997 Apr 4;272(14):9410-6 [9083079.001]
  • [Cites] Cancer Res. 1997 May 1;57(9):1814-9 [9135027.001]
  • [Cites] Cell. 2000 Oct 13;103(2):211-25 [11057895.001]
  • [Cites] Neuron. 2000 Dec;28(3):819-33 [11163269.001]
  • [Cites] Bull Cancer. 2000 Dec;87(12):873-6 [11174115.001]
  • [Cites] Ann Diagn Pathol. 2001 Feb;5(1):10-4 [11172201.001]
  • [Cites] Blood. 1994 Oct 15;84(8):2467-71 [7919366.001]
  • [Cites] J Biochem. 1994 Jun;115(6):1088-96 [7982887.001]
  • [Cites] Cancer Res. 1995 Apr 15;55(8):1792-7 [7712489.001]
  • [Cites] Cytogenet Cell Genet. 1995;70(1-2):143-4 [7736780.001]
  • [Cites] Ann N Y Acad Sci. 1995 Sep 7;766:442-58 [7486690.001]
  • [Cites] Cancer Res. 1996 Jan 1;56(1):100-4 [8548747.001]
  • [Cites] Nat Med. 1996 May;2(5):561-6 [8616716.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4181-6 [8633037.001]
  • [Cites] Cancer Res. 1996 Jun 1;56(11):2515-8 [8653688.001]
  • [Cites] J Biol Chem. 1996 Aug 30;271(35):21446-52 [8702927.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14753-8 [8962127.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Dec 10;93(25):14759-64 [8962128.001]
  • [Cites] Oncogene. 1997 Jan 30;14(4):439-49 [9053841.001]
  • [Cites] Blood. 1997 Feb 15;89(4):1394-404 [9028963.001]
  • [Cites] Cell Signal. 2007 Apr;19(4):740-7 [17110082.001]
  • [Cites] PLoS One. 2007;2(2):e255 [17327916.001]
  • [Cites] Mod Pathol. 2007 Mar;20(3):310-9 [17277765.001]
  • [Cites] Cell. 2007 Mar 9;128(5):961-75 [17350579.001]
  • [Cites] Oncogene. 1997 May 8;14(18):2175-88 [9174053.001]
  • [Cites] Biochim Biophys Acta. 1997 Dec 9;1333(3):F217-48 [9426205.001]
  • [Cites] Blood. 1998 Mar 15;91(6):2076-84 [9490693.001]
  • [Cites] Cancer Res. 1998 Mar 1;58(5):1057-62 [9500471.001]
  • [Cites] Leuk Lymphoma. 1998 Apr;29(3-4):249-56 [9684923.001]
  • [Cites] Am J Pathol. 1998 Sep;153(3):875-86 [9736036.001]
  • [Cites] Blood. 1998 Nov 15;92(10):3591-8 [9808552.001]
  • [Cites] Mol Cell Biol. 1998 Dec;18(12):6951-61 [9819383.001]
  • [Cites] Am J Clin Pathol. 1999 Jan;111(1 Suppl 1):S56-67 [9894470.001]
  • [Cites] Blood. 1999 Apr 15;93(8):2697-706 [10194450.001]
  • [Cites] J Biol Chem. 1999 Apr 30;274(18):12474-9 [10212223.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3913-21 [10339500.001]
  • [Cites] Am J Pathol. 1999 Jun;154(6):1657-63 [10362790.001]
  • [Cites] Cancer Res. 1999 Jun 15;59(12):2776-80 [10383129.001]
  • [Cites] Blood. 1999 Jul 1;94(1):362-4 [10381534.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] J Med Chem. 2004 Dec 30;47(27):6658-61 [15615512.001]
  • [Cites] Clin Lung Cancer. 2004 Dec;6 Suppl 1:S20-3 [15638953.001]
  • [Cites] Cancer Sci. 2005 Jan;96(1):54-6 [15649256.001]
  • [Cites] Eur J Neurosci. 2005 Jan;21(2):513-21 [15673450.001]
  • [Cites] J Clin Pharmacol. 2005 Apr;45(4):394-403 [15778420.001]
  • [Cites] Oncogene. 2005 Apr 28;24(19):3206-15 [15735675.001]
  • [Cites] Cancer Lett. 2005 Jul 8;225(1):1-26 [15922853.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jul 15;332(4):1146-52 [15949466.001]
  • [Cites] Am J Pathol. 2005 Jul;167(1):213-22 [15972965.001]
  • [Cites] Haematologica. 2005 Jul;90(7):988-90 [15996942.001]
  • [Cites] Methods Mol Med. 2005;115:271-94 [15998974.001]
  • [Cites] J Biol Chem. 2005 Jul 15;280(28):26039-48 [15886198.001]
  • [Cites] J Biol Chem. 2005 Jul 22;280(29):26953-64 [15908427.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):796-801 [15602716.001]
  • [Cites] Semin Cancer Biol. 2005 Dec;15(6):506-14 [16154360.001]
  • [Cites] J Pediatr Surg. 2005 Oct;40(10):1581-6 [16226988.001]
  • [Cites] Int J Cancer. 2005 Dec 20;117(6):942-51 [15986444.001]
  • [Cites] Curr Mol Med. 2005 Nov;5(7):625-42 [16305489.001]
  • [Cites] Dev Genes Evol. 2006 Jan;216(1):10-8 [16220264.001]
  • [Cites] Int J Cancer. 2006 Mar 1;118(5):1181-6 [16161041.001]
  • [Cites] J Comp Neurol. 2006 Mar 10;495(2):202-12 [16435287.001]
  • [Cites] J Med Chem. 2006 Feb 9;49(3):1006-15 [16451066.001]
  • [Cites] Blood. 2006 Feb 15;107(4):1617-23 [16254137.001]
  • [Cites] Cancer Lett. 2006 Feb 20;233(1):16-20 [15878231.001]
  • [Cites] Oncogene. 2006 May 25;25(22):3150-9 [16501609.001]
  • [Cites] Gene Expr Patterns. 2006 Jun;6(5):448-61 [16458083.001]
  • [Cites] J Med Chem. 2006 Sep 21;49(19):5759-68 [16970400.001]
  • [Cites] J Neural Transm (Vienna). 2006 Oct;113(10):1569-73 [16604305.001]
  • [Cites] J Biol Chem. 2006 Oct 13;281(41):30857-64 [16901907.001]
  • [Cites] Lancet. 2006 Oct 14;368(9544):1303-4 [17046443.001]
  • [Cites] Med Res Rev. 2008 May;28(3):372-412 [17694547.001]
  • [Cites] Exp Hematol. 2006 Dec;34(12):1670-9 [17157164.001]
  • [Cites] Hum Pathol. 2001 Apr;32(4):428-33 [11331960.001]
  • [Cites] Nature. 2001 May 17;411(6835):355-65 [11357143.001]
  • [Cites] J Biol Chem. 2001 May 18;276(20):16772-9 [11278720.001]
  • [Cites] Br J Haematol. 2001 May;113(2):275-95 [11380391.001]
  • [Cites] Am J Surg Pathol. 2001 Jun;25(6):761-8 [11395553.001]
  • [Cites] Mod Pathol. 2001 Jun;14(6):569-76 [11406658.001]
  • [Cites] Genes Cells. 2001 Jun;6(6):531-44 [11442633.001]
  • [Cites] Am J Pathol. 2001 Aug;159(2):411-5 [11485898.001]
  • [Cites] Am J Surg Pathol. 2001 Nov;25(11):1364-71 [11684952.001]
  • [Cites] Cell. 2001 Nov 2;107(3):387-98 [11701128.001]
  • [Cites] Lancet. 2001 Oct 27;358(9291):1421-3 [11705489.001]
  • [Cites] Clin Cancer Res. 2002 Jan;8(1):240-5 [11801565.001]
  • [Cites] N Engl J Med. 2002 Feb 28;346(9):645-52 [11870241.001]
  • [Cites] Blood. 2002 Mar 15;99(6):1928-37 [11877262.001]
  • [Cites] J Biol Chem. 2002 Apr 19;277(16):14153-8 [11809760.001]
  • [Cites] Oncogene. 2002 May 13;21(21):3314-33 [12032772.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10700-5 [12149456.001]
  • [Cites] Oncogene. 2002 Aug 29;21(38):5823-34 [12185581.001]
  • [Cites] J Biol Chem. 2002 Aug 30;277(35):32071-7 [12070152.001]
  • [Cites] J Biochem. 2002 Sep;132(3):359-71 [12204104.001]
  • [Cites] Mod Pathol. 2002 Sep;15(9):931-8 [12218210.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35862-8 [12107166.001]
  • [Cites] J Biol Chem. 2002 Sep 27;277(39):35990-8 [12122009.001]
  • [Cites] Histopathology. 2002 Nov;41(5):461-7 [12405914.001]
  • [Cites] Ai Zheng. 2002 Jan;21(1):58-62 [12500399.001]
  • [Cites] Genes Chromosomes Cancer. 2003 May;37(1):98-105 [12661011.001]
  • [Cites] Pathol Oncol Res. 2003;9(1):13-9 [12704441.001]
  • [Cites] Br J Cancer. 2003 May 19;88(10):1522-6 [12771916.001]
  • [Cites] Eur J Neurosci. 2003 May;17(10):2127-34 [12786979.001]
  • [Cites] Science. 2003 Aug 8;301(5634):805-9 [12907793.001]
  • [Cites] Mod Pathol. 2003 Aug;16(8):828-32 [12920229.001]
  • [Cites] EMBO Rep. 2003 Aug;4(8):781-6 [12855999.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2638-41 [12750159.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2568-73 [12763927.001]
  • [Cites] Blood. 2003 Oct 1;102(7):2642-4 [12816858.001]
  • [Cites] J Pediatr Surg. 2003 Sep;38(9):1296-304 [14523809.001]
  • [Cites] Nature. 2003 Oct 2;425(6957):507-12 [14523446.001]
  • [Cites] Nature. 2003 Oct 2;425(6957):512-6 [14523447.001]
  • [Cites] Cancer Res. 2003 Nov 1;63(21):7345-55 [14612533.001]
  • [Cites] Science. 2003 Dec 5;302(5651):1760-5 [14615545.001]
  • [Cites] Nature. 2003 Dec 18;426(6968):789-96 [14685227.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):127-43 [15013213.001]
  • [Cites] Cancer Res. 2004 May 1;64(9):3256-64 [15126367.001]
  • [Cites] Hum Pathol. 2004 Jun;35(6):711-21 [15188137.001]
  • [Cites] Nature. 2004 Jul 15;430(6997):345-50 [15208641.001]
  • [Cites] Science. 2004 Jul 16;305(5682):399-401 [15256671.001]
  • [Cites] Brain Res Dev Brain Res. 2004 Sep 17;152(2):189-97 [15351507.001]
  • [Cites] J Cell Sci. 2004 Oct 15;117(Pt 22):5405-15 [15466886.001]
  • [Cites] Br J Haematol. 1989 Jan;71(1):31-6 [2917127.001]
  • [Cites] Blood. 1989 Feb 15;73(3):806-13 [2537120.001]
  • [Cites] Leukemia. 1989 Dec;3(12):866-70 [2555633.001]
  • [Cites] J Cell Biol. 1990 Mar;110(3):607-16 [1689730.001]
  • [Cites] Br J Haematol. 1990 Feb;74(2):161-8 [2156548.001]
  • [Cites] Am J Surg Pathol. 1990 Apr;14(4):305-16 [2157342.001]
  • [Cites] Science. 1990 Dec 21;250(4988):1690-4 [2270483.001]
  • [Cites] J Biol Chem. 1992 Feb 5;267(4):2582-7 [1733956.001]
  • [Cites] J Biol Chem. 1992 Jun 5;267(16):11408-16 [1597470.001]
  • [Cites] J Biol Chem. 1992 Dec 25;267(36):25889-97 [1464602.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):679-82 [8421705.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] J Biol Chem. 1994 Apr 29;269(17):12999-3004 [8175719.001]
  • [Cites] Oncogene. 1994 Jun;9(6):1567-74 [8183550.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3389-95 [18451166.001]
  • [Cites] Br J Cancer. 2008 May 6;98(9):1536-9 [18414414.001]
  • [Cites] Curr Opin Genet Dev. 2008 Feb;18(1):87-96 [18406132.001]
  • [Cites] Cancer Sci. 2008 Jul;99(7):1319-25 [18452557.001]
  • [Cites] Hum Pathol. 2008 Jun;39(6):846-56 [18400254.001]
  • [Cites] Biochem Biophys Res Commun. 2008 Jul 25;372(2):351-5 [18501703.001]
  • [Cites] Blood. 2008 Jun 15;111(12):5496-504 [18385450.001]
  • [Cites] Cancer Res. 2008 Jul 1;68(13):4971-6 [18593892.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4275-83 [18594010.001]
  • [Cites] Lung Cancer. 2008 Aug;61(2):163-9 [18242762.001]
  • [Cites] J Biol Chem. 2008 Sep 5;283(36):25036-45 [18599487.001]
  • [Cites] Blood. 2008 Oct 1;112(7):2965-8 [18660380.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):930-5 [18724359.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):967-70 [18923523.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7 [19064915.001]
  • [Cites] Oncogene. 2008 Apr 24;27(19):2728-36 [17998938.001]
  • [Cites] Semin Radiat Oncol. 2007 Jan;17(1):62-9 [17185199.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5 [17185414.001]
  • [Cites] J Neurochem. 2006 Dec;99(6):1470-9 [17230638.001]
  • [Cites] FEBS Lett. 2007 Feb 20;581(4):727-34 [17274988.001]
  • [Cites] Cancer Control. 2007 Apr;14(2):124-32 [17387297.001]
  • [Cites] Am J Surg Pathol. 2007 Apr;31(4):509-20 [17414097.001]
  • [Cites] Am J Clin Pathol. 2007 May;127(5):670-86 [17439828.001]
  • [Cites] Cancer Res. 2007 Apr 15;67(8):3529-34 [17440059.001]
  • [Cites] Nat Rev Cancer. 2007 May;7(5):345-56 [17457302.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4278-86 [17483340.001]
  • [Cites] Cancer Res. 2007 May 1;67(9):4408-17 [17483355.001]
  • [Cites] Leuk Lymphoma. 2007 May;48(5):1053-6 [17487757.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Jun 29;358(2):399-403 [17490616.001]
  • [Cites] Oncology (Williston Park). 2007 May;21(6):689-96; discussion 699-700, [17564326.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1349-57 [17537667.001]
  • [Cites] J Mol Med (Berl). 2007 Aug;85(8):863-75 [17318615.001]
  • [Cites] Exp Hematol. 2007 Aug;35(8):1240-8 [17560012.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Oncogene. 2007 Aug 16;26(38):5606-14 [17353907.001]
  • [Cites] Blood. 2007 Sep 1;110(5):1621-30 [17416736.001]
  • [Cites] Biochem Biophys Res Commun. 2007 Oct 12;362(1):5-10 [17706593.001]
  • [Cites] Ann Oncol. 2007 Sep;18 Suppl 10:x25-31 [17761720.001]
  • [Cites] Blood. 2007 Oct 1;110(7):2600-9 [17537995.001]
  • [Cites] J Biol Chem. 2007 Sep 28;282(39):28683-90 [17681947.001]
  • [Cites] Nat Rev Drug Discov. 2007 Oct;6(10):834-48 [17853901.001]
  • [Cites] Cell Signal. 2007 Dec;19(12):2434-43 [17904822.001]
  • [Cites] Blood. 2007 Nov 1;110(9):3374-83 [17690253.001]
  • [Cites] Nat Med. 2007 Nov;13(11):1341-8 [17922009.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 11;104(50):19936-41 [18077425.001]
  • [Cites] Cell. 2007 Dec 14;131(6):1190-203 [18083107.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 [18089725.001]
  • [Cites] Nat Rev Cancer. 2008 Jan;8(1):11-23 [18097461.001]
  • [Cites] J Thorac Oncol. 2008 Jan;3(1):13-7 [18166835.001]
  • [Cites] Nat Biotechnol. 2008 Jan;26(1):127-32 [18183025.001]
  • [Cites] Neuropsychopharmacology. 2008 Feb;33(3):685-700 [17487225.001]
  • [Cites] Recent Pat Anticancer Drug Discov. 2007 Jun;2(2):175-86 [18221061.001]
  • [Cites] Pediatr Clin North Am. 2008 Feb;55(1):97-120, x [18242317.001]
  • [Cites] Oncology (Williston Park). 2007 Dec;21(14):1696-706; discussion 1706-9, 1712, 1715 [18247017.001]
  • [Cites] Hum Pathol. 2008 Mar;39(3):410-9 [18261625.001]
  • [Cites] J Biol Chem. 2008 Feb 15;283(7):3743-50 [18070884.001]
  • [Cites] Curr Opin Oncol. 2008 Mar;20(2):162-75 [18300766.001]
  • [Cites] Leuk Res. 2008 Mar;32(3):383-93 [17720243.001]
  • [Cites] Neoplasia. 2008 Mar;10(3):298-302 [18320074.001]
  • [Cites] J Clin Oncol. 2008 Apr 1;26(10):1742-51 [18375904.001]
  • [Cites] J Clin Pathol. 2008 Apr;61(4):428-37 [17938159.001]
  • [Cites] Curr Opin Hematol. 2008 May;15(3):210-4 [18391787.001]
  • (PMID = 19275511.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA069129-10; United States / NCI NIH HHS / CA / R01 CA69129; United States / NCI NIH HHS / CA / R01 CA069129; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / R01 CA069129-10
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Carrier Proteins; 0 / Cytokines; 0 / Enzyme Inhibitors; 0 / Nuclear Proteins; 117896-08-9 / nucleophosmin; 134034-50-7 / pleiotrophin; 137497-38-2 / midkine; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Number-of-references] 304
  • [Other-IDs] NLM/ NIHMS105118; NLM/ PMC2780428
  •  go-up   go-down


83. O'leary H, Savage KJ: The spectrum of peripheral T-cell lymphomas. Curr Opin Hematol; 2009 Jul;16(4):292-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The spectrum of peripheral T-cell lymphomas.
  • PURPOSE OF REVIEW: This review summarizes recent progress that has advanced our understanding of the pathobiology and prognosis of peripheral T-cell lymphomas including the changes introduced to the updated World Health Organization classification of lymphoid neoplasms.
  • RECENT FINDINGS: The International Peripheral T-Cell Lymphoma Project was a large collaborative project, highlighting the clinico-pathologic and geographic differences of this diverse group of diseases.
  • Peripheral T-cell lymphoma, not otherwise specified, is a biologically heterogeneous subtype, and a number of studies including investigations using molecular profiling have explored whether meaningful prognostic or biologic subgroups can be identified.
  • Angioimmunoblastic T-cell lymphoma demonstrates overlapping immunophenotypical and molecular features with normal follicular T-helper cells, giving some insight into the cell of origin.
  • Systemic anaplastic large cell lymphoma is composed of two disease groups based on the presence or absence of anaplastic lymphoma kinase overexpression.
  • Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma has a significantly better prognosis than anaplastic lymphoma kinase-negative anaplastic large cell lymphoma and molecular studies have illustrated that each entity has a distinct molecular profile.
  • Anaplastic lymphoma kinase-negative anaplastic large cell lymphoma has been recently shown to have a more favourable, but still unsatisfactory, prognosis than peripheral T-cell lymphoma, not otherwise specified, and biological and molecular distinctions confirm that they are separate entities.
  • SUMMARY: Advances are being made in understanding the unique pathobiology of the peripheral T-cell lymphoma subtypes that will help to refine diagnoses, identify potential prognostic markers, elucidate the molecular mechanisms critical in disease pathogenesis and define new therapeutic targets in the poor-risk population.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / classification. Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Antigens, Neoplasm / genetics. Cyclin A / genetics. Cyclin B / genetics. DNA Topoisomerases, Type II / genetics. DNA-Binding Proteins / genetics. Gene Expression Profiling. Humans. Prognosis. Proliferating Cell Nuclear Antigen / genetics. Survival Analysis. World Health Organization

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19509496.001).
  • [ISSN] 1531-7048
  • [Journal-full-title] Current opinion in hematology
  • [ISO-abbreviation] Curr. Opin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cyclin A; 0 / Cyclin B; 0 / DNA-Binding Proteins; 0 / Proliferating Cell Nuclear Antigen; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  • [Number-of-references] 47
  •  go-up   go-down


84. Cerveny CG, Law CL, McCormick RS, Lenox JS, Hamblett KJ, Westendorf LE, Yamane AK, Petroziello JM, Francisco JA, Wahl AF: Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics. Leukemia; 2005 Sep;19(9):1648-55
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Signaling via the anti-CD30 mAb SGN-30 sensitizes Hodgkin's disease cells to conventional chemotherapeutics.
  • SGN-30, a monoclonal antibody with activity against CD30+ malignancies, is currently in phase II clinical evaluation for treatment of Hodgkin's disease (HD) and anaplastic large cell lymphoma.
  • In addition to direct cell killing, SGN-30 affects growth arrest and drug sensitization through growth regulating and proapoptotic machinery.
  • Importantly, these data suggest that SGN-30 can enhance the efficacy of standard chemotherapies used to treat patients with CD30+ malignancies.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antigens, CD30 / immunology. Hodgkin Disease / drug therapy. Hodgkin Disease / immunology. Signal Transduction / immunology
  • [MeSH-minor] Animals. Apoptosis / drug effects. Bleomycin / therapeutic use. Cell Cycle / drug effects. Cell Cycle / immunology. Cell Line, Tumor. Drug Therapy, Combination. Humans. Mice. Mice, SCID. NF-kappa B / drug effects. NF-kappa B / immunology. Oligonucleotide Array Sequence Analysis / methods. Sensitivity and Specificity. Xenograft Model Antitumor Assays / methods


85. Harbell JW, Dunn TB, Fauda M, John DG, Goldenberg AS, Teperman LW: Transmission of anaplastic large cell lymphoma via organ donation after cardiac death. Am J Transplant; 2008 Jan;8(1):238-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transmission of anaplastic large cell lymphoma via organ donation after cardiac death.
  • We present a case of anaplastic T-cell lymphoma transmitted to four recipients of solid organ transplants from a DCD donor suspected of having bacterial meningitis.
  • On brain biopsy, the donor was found to have anaplastic central nervous system T-cell lymphoma, and the recipient of the donor's pancreas, liver and kidneys were found to have involvement of T-cell lymphoma.
  • In cases of lymphoma transmission, excision of the graft may be the only chance at long-term survival.
  • [MeSH-major] Death. Lymphoma, Large-Cell, Anaplastic / diagnosis. Lymphoma, Large-Cell, Anaplastic / etiology. Organ Transplantation / adverse effects. Tissue Donors


86. Baumforth KR, Flavell JR, Reynolds GM, Davies G, Pettit TR, Wei W, Morgan S, Stankovic T, Kishi Y, Arai H, Nowakova M, Pratt G, Aoki J, Wakelam MJ, Young LS, Murray PG: Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells. Blood; 2005 Sep 15;106(6):2138-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Induction of autotaxin by the Epstein-Barr virus promotes the growth and survival of Hodgkin lymphoma cells.
  • A proportion of patients with Hodgkin lymphoma carry Epstein-Barr virus (EBV), an oncogenic herpesvirus, in their tumor cells.
  • Although it is generally assumed that EBV contributes to the malignant phenotype of Hodgkin lymphoma cells, direct evidence in support of this is lacking.
  • Here we show that EBV infection of Hodgkin lymphoma cells results in the induction of autotaxin, a secreted tumor-associated factor with lysophospholipase-D activity.
  • Up-regulation of autotaxin increased the generation of lysophosphatidic acid (LPA) and led to the enhanced growth and survival of Hodgkin lymphoma cells, whereas specific down-regulation of autotaxin decreased LPA levels and reduced cell growth and viability.
  • In lymphoma tissues, autotaxin expression was mainly restricted to CD30+ anaplastic large-cell lymphomas and Hodgkin lymphoma; in the latter, high levels of autotaxin were strongly associated with EBV positivity (P = .006).
  • Our results identify the induction of autotaxin and the subsequent generation of LPA as key molecular events that mediate the EBV-induced growth and survival of Hodgkin lymphoma cells and suggest that this pathway may provide opportunities for novel therapeutic intervention.
  • [MeSH-major] Cell Proliferation. Gene Expression Regulation, Neoplastic. Glucose-6-Phosphate Isomerase / genetics. Glycoproteins / genetics. Herpesvirus 4, Human / physiology. Hodgkin Disease / pathology. Hodgkin Disease / virology. Multienzyme Complexes / genetics
  • [MeSH-minor] Cell Line, Tumor. Cell Survival. Epstein-Barr Virus Infections / metabolism. Humans. Lysophospholipids / biosynthesis. Phosphodiesterase I. Phosphoric Diester Hydrolases. Pyrophosphatases. Up-Regulation

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15933052.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Glycoproteins; 0 / Lysophospholipids; 0 / Multienzyme Complexes; 22002-87-5 / lysophosphatidic acid; EC 3.1.4.- / Phosphoric Diester Hydrolases; EC 3.1.4.1 / Phosphodiesterase I; EC 3.1.4.39 / alkylglycerophosphoethanolamine phosphodiesterase; EC 3.6.1.- / Pyrophosphatases; EC 5.3.1.9 / Glucose-6-Phosphate Isomerase
  •  go-up   go-down


87. Che C, Liu L, Gong J, Yang Y, Wang G, Quan J, Yang Z: Construction of all-carbon quaternary center by R2AlCl-mediated ring-opening reaction of oxacycles. Org Lett; 2010 Feb 5;12(3):488-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • An unexpected R(2)AlCl-mediated ring-opening reaction of oxacycles for the formation of all-carbon quaternary centers was discovered, and a possible mechanism is proposed.
  • The developed chemistry provides a concise approach to synthesize structural diverse of dolastane-type compounds.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20047283.001).
  • [ISSN] 1523-7052
  • [Journal-full-title] Organic letters
  • [ISO-abbreviation] Org. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diterpenes
  •  go-up   go-down


88. Oflazoglu E, Kissler KM, Sievers EL, Grewal IS, Gerber HP: Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma. Br J Haematol; 2008 Jul;142(1):69-73
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma.
  • The antibody-drug conjugate (ADC) cAC10-vcMMAE consists of the tubulin inhibitor monomethyl auristatin E (MMAE) conjugated to the chimeric anti-CD30 monoclonal antibody cAC10.
  • This ADC potently interferes with the growth of CD30-positive haematological tumours, including Hodgkin lymphoma (HL) and anaplastic large-cell lymphoma.
  • [MeSH-major] Antigens, CD30 / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hodgkin Disease / therapy. Immunoconjugates / administration & dosage. Oligopeptides / administration & dosage. Tubulin Modulators / administration & dosage

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 2000 Jul;18(13):2615-9 [10893294.001]
  • [Cites] Cancer Res. 2002 Jul 1;62(13):3736-42 [12097283.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):607-14 [12586796.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1458-65 [12714494.001]
  • [Cites] J Clin Oncol. 2003 Sep 15;21(18):3526-34 [12972530.001]
  • [Cites] Oncologist. 2007 Feb;12(2):156-67 [17296811.001]
  • [Cites] Annu Rev Immunol. 1998;16:471-93 [9597138.001]
  • [Cites] In Vivo. 2005 Mar-Apr;19(2):439-53 [15796209.001]
  • [Cites] Haematologica. 2005 Dec;90(12):1680-92 [16330443.001]
  • [Cites] Curr Opin Mol Ther. 2006 Apr;8(2):164-72 [16610770.001]
  • [Cites] Cancer Biol Ther. 2005 Aug;4(8):866-71 [16210917.001]
  • [Cites] Clin Cancer Res. 2004 Oct 15;10(20):7063-70 [15501986.001]
  • (PMID = 18477046.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, CD30; 0 / Immunoconjugates; 0 / Oligopeptides; 0 / Tubulin Modulators; 0 / monomethyl auristatin E; 0W860991D6 / Deoxycytidine; 11056-06-7 / Bleomycin; 5V9KLZ54CY / Vinblastine; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; B76N6SBZ8R / gemcitabine; ABVD protocol
  • [Other-IDs] NLM/ PMC2440525
  •  go-up   go-down


89. Niitsu N, Kohri M, Hayama M, Tamaru J, Miura I: ALK-positive anaplastic large cell lymphoma with dic(2;4)(p23;q33). Leuk Res; 2009 Jun;33(6):e23-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] ALK-positive anaplastic large cell lymphoma with dic(2;4)(p23;q33).
  • [MeSH-major] Chromosomes, Human, Pair 2. Chromosomes, Human, Pair 4. Lymphoma, Large-Cell, Anaplastic / genetics. Protein-Tyrosine Kinases / metabolism. Translocation, Genetic

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19036440.001).
  • [ISSN] 1873-5835
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  •  go-up   go-down


90. Bittencourt AL, Rothers S, Boente P, Santos R: Primary cutaneous eosinophil-rich anaplastic large cell lymphoma: report of an unusual case and literature review. J Cutan Med Surg; 2008 Mar-Apr;12(2):88-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous eosinophil-rich anaplastic large cell lymphoma: report of an unusual case and literature review.
  • BACKGROUND: Cutaneous, neutrophil-rich anaplastic large cell lymphoma (ALCL) is an uncommon variant of ALCL that may be confused with inflammatory dermatoses.
  • OBJECTIVE AND METHODS: We describe an eosinophil-rich variant of ALCL occurring on the left ear without systemic involvement.
  • The lesion had inflammatory characteristics, which led initially to a histological diagnosis of an inflammatory process.
  • Two months later, a second biopsy diagnosed eosinophil-rich variant of ALCL.
  • We discuss the clinicopathological findings and the differential diagnosis CONCLUSIONS: To the best of our knowledge, the occurrence of a cutaneous, eosinophil-rich variant of ALCL has not been previously reported.
  • It is important to alert pathologists to this variant of ALCL so that this possibility may be considered in the early differential diagnosis of inflammatory cutaneous conditions.
  • [MeSH-major] Ear Neoplasms / metabolism. Ear, External. Eosinophils / metabolism. Lymphoma, Primary Cutaneous Anaplastic Large Cell / metabolism. Skin Neoplasms / metabolism
  • [MeSH-minor] Aged, 80 and over. Diagnosis, Differential. Humans. Immunohistochemistry. Male. Skin Diseases / diagnosis


91. Hochberg J, Waxman IM, Kelly KM, Morris E, Cairo MS: Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science. Br J Haematol; 2009 Jan;144(1):24-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adolescent non-Hodgkin lymphoma and Hodgkin lymphoma: state of the science.
  • Lymphoma is the most common malignancy among adolescents, accounting for >25% of newly diagnosed cancers in the 15-19 year age group.
  • Hodgkin lymphoma (HL) accounts for the majority (two-thirds) of cases, while the remainder of patients have one of four subtypes of non-Hodgkin lymphoma (NHL): diffuse large B-cell lymphoma (DLBCL) including primary mediastinal B-cell lymphoma (PMBL), Burkitt lymphoma (BL), lymphoblastic lymphoma (LL) or anaplastic large cell lymphoma (ALCL).
  • Adolescent lymphoma is particularly interesting because it often shares features with both childhood and adult lymphoma.
  • This review details the complexities associated with the diagnosis and treatment of adolescent lymphoma and updates the state of the science, with particular emphasis on epidemiology, diagnosis, and proper management of HL and the various subtypes of NHL.
  • [MeSH-major] Hodgkin Disease / diagnosis. Lymphoma, Non-Hodgkin / diagnosis

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19087093.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Number-of-references] 115
  •  go-up   go-down


92. Querfeld C, Khan I, Mahon B, Nelson BP, Rosen ST, Evens AM: Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options. Oncology (Williston Park); 2010 Jun;24(7):574-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous and systemic anaplastic large cell lymphoma: clinicopathologic aspects and therapeutic options.
  • Anaplastic large cell lymphoma (ALCL) is a biologic and clinically heterogenous subtype of T-cell lymphoma.
  • Clinically, ALCL may present as localized (primary) cutaneous disease or widespread systemic disease.
  • These two forms of ALCL are distinct entities with different clinical and biologic features.
  • Both types share similar histology, however, with cohesive sheets of large lymphoid cells expressing the Ki-1 (CD30) molecule.
  • Primary cutaneous ALCL (C-ALCL) is part of the spectrum of CD30+ lymphoproliferative diseases of the skin including lymphomatoid papulosis.
  • Using conservative measures, 5-year disease-free survival rates are > 90%.
  • The systemic ALCL type is an aggressive lymphoma that may secondarily involve the skin, in addition to other extranodal sites.
  • Further, systemic ALCL may be divided based on the expression of anaplastic lymphoma kinase (ALK) protein, which is activated most frequently through the nonrandom t(2;5) chromosome translocation, causing the fusion of the nucleophosmin (NPM) gene located at 5q35 to 2p23 encoding the receptor tyrosine kinase ALK.
  • Systemic ALK+ ALCLs have improved prognosis compared with ALK-negative ALCL, although both subtypes warrant treatment with polychemotherapy.
  • Allogeneic and, to a lesser extent, autologous stem cell transplantation play a role in relapsed disease, while the benefit of upfront transplant is not clearly defined.
  • In addition, a multitude of novel therapeutics are being studied, including anti-CD30 antibodies, histone deacetylase inhibitors, immunomodulatory drugs, proteasome inhibitors, and inhibitors of ALK and its downstream signaling pathways.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / pathology. Lymphoma, Large-Cell, Anaplastic / therapy. Lymphoma, Primary Cutaneous Anaplastic Large Cell / pathology. Lymphoma, Primary Cutaneous Anaplastic Large Cell / therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy
  • [MeSH-minor] Antigens, CD30 / physiology. Humans. Immunophenotyping

  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2010 Jun;24(7):587, 592-3 [20669795.001]
  • [CommentIn] Oncology (Williston Park). 2010 Jun;24(7):594 [20669796.001]
  • (PMID = 20669794.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD30
  • [Number-of-references] 118
  •  go-up   go-down


93. Prinz H, Böhm KJ, Müller K: Synthesis of 2,6-aceanthrylenedione, a cyclic vinylog of anthraquinone. J Org Chem; 2010 Jun 4;75(11):3867-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The first synthesis of 2,6-aceanthrylenedione (6), a cyclic vinylog of anthraquinone and a useful starting material for the synthesis of 1-phenylaceanthrylene-2,6-diones such as 7, 8, and 9, is described. (10-Oxo-10H-anthracen-9-ylidene) acetyl chloride (5) cyclizes intramolecularly at room temperature in the presence of AlCl(3) to give 6.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20459073.001).
  • [ISSN] 1520-6904
  • [Journal-full-title] The Journal of organic chemistry
  • [ISO-abbreviation] J. Org. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracenes; 0 / Anthraquinones; 0 / Tubulin Modulators; 202-03-9 / aceanthrylene
  •  go-up   go-down


94. Gan MF, Lu HS, Zhang JW, Yu XR: [Interdigitating dendritic cell sarcoma/tumor: a study of 3 cases]. Zhonghua Bing Li Xue Za Zhi; 2008 Oct;37(10):676-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Interdigitating dendritic cell sarcoma/tumor: a study of 3 cases].
  • OBJECTIVE: To study the pathologic features, diagnosis and differential diagnosis of interdigitating dendritic cell sarcoma (IDCS).
  • METHODS: The clinical findings, morphologic features and immunophenotype of 3 cases of IDCS were investigated.
  • They were oval to spindle in shape and contained pale eosinophilic cytoplasm, oval and sometimes grooved nuclei, small distinct nucleoli and ill-defined cell borders.
  • CONCLUSIONS: IDCS is a rare type of histiocytic and dendritic cell malignancy with distinctive morphologic findings.
  • It needs to be distinguished from follicular dendritic cell sarcoma, inflammatory pseudotumor, Langerhans' cell histiocytosis, malignant melanoma, undifferentiated carcinoma and anaplastic large cell lymphoma.
  • Immunohistochemical staining for S-100 protein is helpful in confirming the diagnosis.
  • [MeSH-major] Dendritic Cell Sarcoma, Follicular / pathology. Dendritic Cell Sarcoma, Interdigitating / pathology. Lymph Nodes / pathology. Lymphatic Metastasis / pathology. S100 Proteins / immunology
  • [MeSH-minor] Adolescent. Carcinoma / pathology. Dendritic Cells / pathology. Diagnosis, Differential. Female. Humans. Male. Middle Aged. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19094486.001).
  • [ISSN] 0529-5807
  • [Journal-full-title] Zhonghua bing li xue za zhi = Chinese journal of pathology
  • [ISO-abbreviation] Zhonghua Bing Li Xue Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / S100 Proteins
  •  go-up   go-down


95. Lau SK, Thomas P, Weiss LM: Immunohistochemical evaluation of CON6D/B5: a new CD30 monoclonal antibody. Appl Immunohistochem Mol Morphol; 2010 May;18(3):273-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Immunohistochemical evaluation of CON6D/B5: a new CD30 monoclonal antibody.
  • Immunohistochemical evaluation of CD30 expression is commonly performed in the assessment of hematopoietic disorders and germ cell tumors.
  • A new monoclonal antibody, CON6D/B5, directed against the CD30 antigen has become commercially available for use in formalin-fixed paraffin-embedded tissue samples.
  • The performance characteristics of CON6D/B5 were tested and compared with the well-characterized monoclonal CD30 antibody Ber-H2.
  • Similar to Ber-H2, CON6D/B5 immunoreactivity was observed in all cases of classical Hodgkin lymphoma, anaplastic large cell lymphoma, and embryonal carcinoma, with no staining detectable in any of the other various tumors evaluated, including several neoplasms earlier reported as showing CD30 positivity by other investigators.
  • The monoclonal antibody CON6D/B5 offers a suitable alternative to Ber-H2 for the immunohistochemical detection of CD30 expression.

  • MedlinePlus Health Information. consumer health - Hodgkin Disease.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20090517.001).
  • [ISSN] 1533-4058
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antigens, CD30; 0 / Epitopes
  •  go-up   go-down


96. Allory Y, Merabet Z, Copie-Bergman C, Lange F, Yiou R, Gaulard P: Sarcomatoid variant of anaplastic large cell lymphoma mimics ALK-1-positive inflammatory myofibroblastic tumor in bladder. Am J Surg Pathol; 2005 Jun;29(6):838-9; author reply 839
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sarcomatoid variant of anaplastic large cell lymphoma mimics ALK-1-positive inflammatory myofibroblastic tumor in bladder.
  • [MeSH-major] Activin Receptors, Type I / immunology. Biomarkers, Tumor / immunology. Lung Neoplasms / immunology. Lymphoma, Large B-Cell, Diffuse / immunology. Urinary Bladder Neoplasms / immunology
  • [MeSH-minor] Activin Receptors, Type II. Aged. Female. Humans


97. Husain SM, Fröhlich R, Schepmann D, Wünsch B: Asymmetric synthesis of enantiomerically pure 2-substituted tetrahydro-3-benzazepines and their affinity to sigma1 receptors. J Org Chem; 2009 Apr 3;74(7):2788-93
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The reduction of the oxazolo[2,3-b][3]benzazepin-5(6H)-ones trans-3 and cis-4 with AlCl(3)/LiAlH(4) (1:3) took place with retention of configuration and yielded 2,3-disubsituted tetrahydro-3-benzazepines 10 and11.

  • Hazardous Substances Data Bank. HYDROGEN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19267485.001).
  • [ISSN] 1520-6904
  • [Journal-full-title] The Journal of organic chemistry
  • [ISO-abbreviation] J. Org. Chem.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzazepines; 0 / Indans; 0 / Oxazoles; 504-76-7 / oxazolidine; 7YNJ3PO35Z / Hydrogen; B926Y9U4QN / indacrinone
  •  go-up   go-down


98. Wu L, Wang Y, Fu SL, Huang L, Tongji FC, Qi JY: Anaplastic large cell lymphoma with primary involvement of skeletal muscle: a rare case report and review of the literature. Pediatr Hematol Oncol; 2009 Apr-May;26(3):142-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anaplastic large cell lymphoma with primary involvement of skeletal muscle: a rare case report and review of the literature.
  • Primary skeletal muscle ALCL is very rare.
  • Here the authors report a case of skeletal muscle ALCL that was proven pathologically.
  • Ultrasonography revealed a low-echo and irregular mass in the left lumbar muscle measuring 8 x 1.4 x 3.6 cm in size and a similar mass 8 x 3.5 x 3.7 cm in size in the femoral muscle of the left thigh.
  • Histopathological examination revealed a diffuse infiltration of large and atypical cells with pleomorphic nuclei and abundant cytoplasm.
  • Immunohistological staining showed these atypical cells were positive for CD30 (Ki-l), anaplastic lymphoma kinase (ALK), epithelial membrane antigen (EMA), CD3, CD45RO, and CD68.
  • The morphology and immunophenotype were consistent with CD30-positive, ALK-positive, and ALCL of T-cell lineage.
  • The patient's condition was diagnosed as CD30-positive primary skeletal muscle ALCL.
  • [MeSH-major] Lymphoma, Large-Cell, Anaplastic / diagnosis. Muscle Neoplasms / diagnosis


99. Schlaak M, Renner R, Treudler R, Harth W, Poenisch W, Kauer F, Grunewald S, Wittekind C, Simon JC: CD30+ anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with an unusual translocation t(11;22). Br J Dermatol; 2008 Jul;159(1):240-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] CD30+ anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with an unusual translocation t(11;22).
  • [MeSH-major] Bone Neoplasms / genetics. Chromosomes, Human, Pair 11 / genetics. Lymphoma, Large-Cell, Anaplastic / genetics. Translocation, Genetic / genetics
  • [MeSH-minor] Adult. Chromosomes, Human, Pair 22 / genetics. Diagnosis, Differential. Humans. Male. Phenotype. Sarcoma, Ewing / genetics


100. Koreen IV, Cho RI, Frueh BR, Elner VM: Primary cutaneous anaplastic large cell lymphoma of the medial canthus and orbit. Ophthal Plast Reconstr Surg; 2009 Jan-Feb;25(1):63-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary cutaneous anaplastic large cell lymphoma of the medial canthus and orbit.
  • Biopsy revealed CD30+ anaplastic large cell lymphoma.
  • Systemic evaluation for lymphoma was negative, and he underwent local radiotherapy.
  • The lesion regressed completely, and he has remained disease free for 7 months.
  • CD30+ anaplastic large cell lymphoma of the periocular skin and orbit are usually distinct, exceedingly rare entities; no reported cases had simultaneous involvement of both tissues.
  • The authors present the first reported case, to their knowledge, of simultaneous skin and orbital involvement by anaplastic large cell lymphoma.
  • [MeSH-major] Eyelid Neoplasms / pathology. Lymphoma, Large-Cell, Anaplastic / pathology. Orbital Neoplasms / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Antigens, CD3 / analysis. Antigens, CD30 / analysis. Humans. Immunoenzyme Techniques. Male. Middle Aged. Tomography, X-Ray Computed






Advertisement